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    1 General Introduction
 Our immune system has evolved to protect us from disease and death caused 
by pathogens including bacteria and viruses. It comprises two separate but 
interacting compartments, the innate and the adaptive immune system. The 
innate immune response constitutes the first line of defense against pathogens 
that have broken through physical barriers such as the skin and mucosal layers. 
Innate immune cells, including macrophages, dendritic cells (DCs), as well as 
neutrophils, basophils, eosinophils and granulocytes harbor receptors (e.g. Toll 
like receptors) that recognize specific conserved patterns on pathogens known as 
PAMPs (pathogen associated molecular patterns). After recognition of PAMPs, 
the innate immune cells become activated which leads to enhanced phagocytosis 
of the pathogens by these cells and production of substances that can destroy 
the pathogens. In addition, immune signaling agents, such as cytokines and 
chemokines are secreted that cause inflammation and attraction of other 
immune cells. NK cells are rapidly responding innate immune cells, which cause 
destruction of virus-infected cells and tumor-cells by secreting granzymes and 
perforin that induce apoptosis. NK cells are regulated by an array of activating 
and inhibiting receptors on their surface (1). Compared to adaptive immune cells 
(i.e. B and T cells), innate immune cells have a limited repertoire of recognition 
and do not posses the ability to generate memory against pathogens, an exclusive 
characteristic of the adaptive immune system. 
The adaptive immune system consists of B cells and T cells. B cells are 
responsible for the humoral response of the adaptive immune repertoire. Upon 
encountering cognate antigen, they divide from low numbers of precursor cells 
into large numbers. Subsequently, B cells either mature into memory B cells or 
into plasma cells, which secrete antibodies that can neutralize pathogens or tag 
them for destruction by the innate immune cells. The cellular component of the 
adaptive response consists of T cells. T cells are divided in CD8+ T cells, cytotoxic 
T cells, and CD4+ T cells, T helper cells and γδ T cells. T cell precursors originate 
in the bone-marrow and develop in the thymus from immature to mature T 
cells by T cell receptor (TCR) rearrangement and selection for specificity. In 
the thymus many epitopes (derived from self proteins) are presented by the 
individual’s major histocompatibility (MHC) molecules, and T cells are selected 
based on affinity towards these MHC-presented epitopes. T cells with no affinity 
to the MHC/epitope complex die of neglect, because they are unable to recognize 
the basic structure of the MHC in which peptides are presented (lack of positive 
selection). T cells carrying T cell receptors with strong affinity for self-epitopes 
are eliminated, because they risk causing auto-immunity (negative selection). 
T cells with low affinity for self MHC-presented epitopes are allowed to expand 
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(positive selection) (2). After these selection processes the T cells leave the 
thymus and circulate in the periphery, residing mostly in secondary lymphoid 
tissue such as lymph nodes and spleen. This is where the naïve T cells will first 
encounter high affinity foreign epitopes. 
Effective priming of T cells is dependent on 1. High affinity TCR engagement 
with MHC molecules presenting the cognate foreign epitope, 2. Interaction with 
costimulatory molecules such as CD80, CD86, and various TNF-(receptor) family 
molecules like CD40, OX40-L, 41BB-L and CD70, present on the cell surface of 
antigen presenting cells (APCs) such as DCs. TCR signals and costimulatory 
signals operate together in the immunological synapse to provide long lasting 
stimulation 3. Cytokines secreted by the APCs, mainly IL-2, IL-12 and IFN-
alpha. The development of naive T cells into effector cells with different functions 
and kinetics, is controlled by the presence and strength of all three types of 
signals (TCR-, Costimulation-, Cytokine-mediated). 
T lymphocytes
 T cells are divided roughly in CD8+ T cells, which recognize epitopes presented 
in MHC Class I molecules, and CD4+ T cells, which recognize epitopes presented 
in MHC Class II molecules. CD4+ T cell differentiation displays great plasticity, 
incorporating many subsets, some of which are definite, others retain the capacity 
to switch from one subset to another, according to present knowledge. There are 
at least 5 different categories known: T helper 1(Th1), T helper 2 (Th2), T helper 
17 (Th17), Regulatory T cells (Treg), and Follicular helper T cells (Tfh). The subset 
distinction is based on the cytokine expression profile: IFN-gamma for Th1, IL-4 
and IL-5 for Th2 and IL-17 for Th17, or the transcription factor responsible for 
subset differentiation, T-bet for Th1, Gata-3 for Th2, Ror-γt for Th17, FoxP3 for 
Treg and Bcl6 for Tfh cells (3, 4). The subsets have different roles in the immune 
system. Th1 cells activate DCs via CD40-CD40L interaction, effectively licensing 
the DC to prime CD8+ T cells into CTLs (5, 6) and provide help to CD8+ T cells 
via cytokine production. Treg cells inhibit T cell responses against self-antigens, 
thereby keeping auto-immunity at bay. Both Th2 and Tfh cells are involved in the 
activation of B cells, and Th2 cells also are important in regulating the innate 
immune response against parasites. 
CD8+ T cells appear to be less heterogeneous but are also found to secrete 
various cytokines and various stages of activation and development, from naïve 
to full effector CTLs and memory cells, are found (7). Several reports describe the 
existence of regulatory CD8+ T cells, but further studies are required in order to 
elucidate their precise physiological role. 
    1
10    
    1 Antigen presentation/DC
Antigens are generally proteins and sometimes carbohydrates nucleic acids or 
lipopeptides and can be derived from self molecules, pathogens and/or other 
non-self materials. Antigen is taken up by professional antigen-presenting cells 
(APCs); B-cells, DCs and macrophages, and processed for presentation. Material 
that is taken up can be either processed in endosomal compartments and loaded 
directly onto MHC II molecules, or proteins can be further cleaved by the 
proteasome into fragments which are then transported into the ER by the TAP 
transporter, where they can be loaded onto the MHC I molecule. Furthermore, 
material taken up can be stored in compartments that facilitate antigen supply 
to MHC Class I for several days (8). Peptides presented in MHC I molecules are 
either derived from the biosynthetic pathway, or in the case of DCs also from 
exogenously ingested proteins, a process referred to as cross-presentation (9). 
Cross-presentation is important in the priming of tumor-specific CD8+ T cells, by 
APCs that have taken up necrotic tumor cell material and present it in MHC I 
molecules, either in the tumor or the tumor-draining LN (10). Peptides presented 
in MHC II molecules, present mainly on APCs and B cells, are generally derived 
from antigen that has been taken up by the APCs and becomes processed via the 
socalled endosomal route (11). 
Lymph nodes
 The lymph node (LN) plays a pivotal role in the immune system. Located at 
strategic places in the body, lymph nodes are the meeting point for different 
immune cells and create the architectural conditions for a productive primary 
or secondary immune response following first, respectively additional encounter 
with antigen. APCs arrive in the lymph node with the afferent lymph, while the 
majority of lymphocytes enter the LN from the bloodstream via high endothelial 
venules (12). Once in the T cell area or the B cell follicle DCs display, based on 
information received in the periphery, antigens in the context that instructs the 
lymphocytes to differentiate into adequate effector cells that are required for 
the situation at hand. Not only APCs appear in the LN through the afferent 
lymph, the interstitial fluid also drains to the LN into the subcapsular sinus. 
From here, the highly specialized conduit system distributes the fluid containing 
only molecules smaller then 70 kD to the B cell follicles and the T cell zone in 
the paracortex, where they can be taken up and presented by resident APCs 
(13, 14). An abundant influx of activated DCs, and danger signals, such as pro-
inflammatory cytokines, heat shock proteins or uric acid can cause the lymph 
node to become reactive, swelling up to several times its original size, due to 
additional influx from both DCs via the afferent lymph and lymphocytes via 
the bloodstream, and reduced egress of lymphocytes from the LN (15-17). This 
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    1process accelerates the normal kinetics of APCs and lymphocyte interactions 
and provides a pro-inflammatory environment.  
Figure 1: Schematic overview of immunological processes within the tumor microenvironment and 
tumor-draining LN. Within the tumor microenvironment and tumor-draining lymph nodes immune cells and 
processes are active, with opposing effects. Tumor promoting inflammation consists of cells like M2-macrophages 
(M2-Mφ), myeloid-derived suppressive cells (MD-suppr.)  and Treg cells and soluble factors like TGF-β, IL-6 and 
VEGF. Tumor inhibiting immunity consists of cells like NK cells, M1-macrophages (M1- Mφ), CD8+ T cells, CD4+ 
T cells, and dendritic cells (DC).
Cancer immune surveillance
 In 1891 the concept of cancer immune surveillance was first postulated, by 
William Coley, who described the ability of the immune system to recognize and 
possibly kill tumor cells (18). This notion was generally overlooked until Burnet 
revived it in the 1960’s (19). He elaborated on the idea that the immune system 
is keeping emerging tumor cells in check, and is capable of preventing malignant 
cells from growing out. Not until decades later data from experimental animal 
models and descriptive studies in patients were published that started to 
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    1 elucidate the molecular and cellular basis behind this theory, as reviewed by 
Swann and Smyth (20). In recent years significant numbers of T cells specific to 
tumor associated antigens have been identified in cancer patients, and several 
studies have correlated pro-inflammatory immune infiltration with improved 
prognosis (21, 22). The concept of immune surveillance was extended by Dunn 
et al. who described the phenomenon called immuno-editing; immunological 
pressure put upon malignant cells by lymphocytes ultimately causing the 
development of tumor cells capable of evading the immune system (23, 24). This 
evasion can be shaped by several different mechanisms, including MHC Class 
I downregulation, antigenic drift, secretion of immune suppressive agents, such 
as TGF-beta, IDO or IL-10, and attraction and expansion of regulatory T cells. 
Many immunotherapy strategies have been studied to intervene with these 
processes, with varying success rates.
Tumor immunotherapy
 Modulating the immune system in order to clear tumors and metastases has been 
the goal of extensive studies in the past few decades. Strategies are generally 
based on either enhancing the tumor specific T cell repertoire, or blocking tumor 
induced immune suppression. Cancer immunotherapies generally employ one 
of four different methods; direct targeting of tumor-associated antigens by 
monoclonal antibodies, vaccination to drive effector T cell responses to tumor-
associated antigens, adoptive transfer of tumor-specific T or NK cells or immune-
modulating monoclonal antibodies.
 Vaccination has long been used to strengthen the immune response against 
pathogens, and is now being used to boost anti-tumor T cell or B cell responses in 
various different forms. Among the most promising for tumor immune therapy 
are vaccinations with synthetic long peptides, and DCs loaded with tumor 
antigen (25-32). Each approach is aimed at expanding the tumor specific T cell 
repertoire and redirecting existing tumor specific T cells into pro-inflammatory 
effector cells. 
 Adoptive transfer strategies have employed tumor specific T cells present in 
tumor tissue or peripheral blood by expanding them in vitro and infuse them back 
into the patients. This process is laborious and costly; however, some promising 
results have been obtained, proving the potential of tumor-specific T-cells (33-36). 
New techniques, designed to increase the number of T cells recognizing tumor 
antigens by introducing T cell receptors through gene transfer are hopeful, and 
are currently being investigated for their potential to be used in the clinic (37, 
38).
Monoclonal antibodies are now established as targeted therapies for several 
diseases including malignancies. Some antibodies target specifically tumor 
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    1cells, such as Herceptin and Rituximab, and tag thereby the tumor cells for 
destruction, leading to enhanced antigen presentation, which indirectly also 
enhances the anti-tumor immune response (39-41). Additionally, a plethora of 
immune-modulating antibodies is available, which can all be used to stimulate 
the anti-tumor immune response. Certain antibodies activate the CD8+ T cell, 
such as 4-1BB agonists, and others activate DCs presenting tumor antigen, such 
as CD40 agonists, or block inhibitory signals for T cells, like PD-1 and CTLA-4 
blocking antibodies (40-46). The use of monoclonal antibodies is expected to grow 
in the next few decades, with more molecules being investigated for their role in 
therapeutic settings.
Outline of this thesis
 This dissertation deals with the role of local immune stimulation in the lymph 
node and tumor microenvironment and its effect on systemic CD8+ T cell 
responses, in particular the anti-tumor CD8+ T cell responses. 
 In chapter 2 the use of a slow-release system is described to deliver the 
immune-activating agonistic CD40 antibody to the tumor-draining area, and the 
advantages of this method over systemic administration of the antibody. The 
local, slow-release administration was very effective in activating a systemic 
anti-tumor effector CD8+ T cell response, to such an extent that a tenfold lower 
dose of antibody could be used without loss of efficacy.  Adverse side-effects, 
analyzed by organ histology and liver enzymes in the blood, were much lower 
upon local anti-CD40 antibody delivery compared to systemic administration. 
The local delivery of anti-CD40 antibody resulted in a systemic anti-tumor CD8+ 
T cell response, capable of clearing distant tumors expressing identical tumor 
antigens.
 Chapter 3 shows that slow-release local administration of CTLA-4 blocking 
antibody can also activate a tumor-specific CD8+ T cell response and cause tumor 
regression, while lowering systemic adverse side-effect as compared to systemic 
administration. CTLA-4 blocking antibody is being widely used in clinical trials, 
and its use has been complicated by induction of auto-immune disease. Here we 
show that using a local low dose injection of CTLA-4 blocking antibody in a slow-
release formulation is equally effective in activating a tumor-specific CD8+ T cell 
response, capable of eradicating tumor cells as systemic high dose treatment.  
 The influence of local lymph node activation on systemic T cell responses is 
further analyzed in chapter 4. CD8+ T cell priming generally occurs in a locally 
inflamed lymph node, called a reactive LN, due to the presence of pathogens. 
The role of the inflammatory milieu on the priming and fate of CD8+ T cells was 
studied by separating the TCR-MHC interaction from the inflammatory cues, by 
priming briefly in vitro followed by transfer to mice with or without  a CpG-induced 
14    
    1 reactive lymph node. The primary CD8+ T cell response was not influenced by 
the presence of a reactive lymph node, however, after a boost vaccination in the 
memory phase, CD8+ T cells primed in the presence of a reactive LN displayed a 
strong quantitative advantage over control CD8+ T cells. The reactive LN, which 
remained swollen with enhanced cellularity for a pronounced period of time, was 
envisaged to act as a shelter for CD8+ T cells while undergoing contraction after 
the primary response. 
 In chapter 5, the advantages and disadvantages of the use of dextran-based 
microparticles as slow-release system for the delivery of immune-activating 
antibodies such as agonistic CD40 in the tumor-draining area are described. 
Dextran-based microparticles can be tailored to release antibodies in desired 
pharmacokinetics, leading to an even further decrease of adverse side-effects, 
as compared to previously described Montanide-ISA 51. However, dextran-
based particles were unexpectedly found to have a stimulating effect on tumor-
outgrowth. This effect coincided with the appearance of large, ulcerated swellings 
at the site of injection.
 In chapter 6, the issues presented in this thesis are discussed. The knowledge 
gained in the work shown here, compared with and strengthened by related 
published work, is used to state the opinion that targeting the tumor-draining 
lymph node and/or tumor microenvironment for immune-activating therapy 
against tumors must be seriously considered.
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Abstract:
Immune-therapy against tumors using anti-CD40 agonistic antibodies has been 
extensively studied in pre-clinical animal models and recently also in clinical 
trials. Although promising results have been obtained, antibody-related toxicity 
has been a limiting factor. We reasoned that strict local activation of tumor-
specific CD8 T cells through stimulation of CD40 on the dendritic cells in the 
tumor area while excluding systemic stimulation might be sufficient for effective 
tumor eradication and can limit systemic toxicity. 
Experimental design:  
Pre-clinical in vivo models for immunogenic tumors were used to investigate 
the potential of delivering a non-toxic dose of agonistic anti-CD40 antibody to 
the tumor region, including draining lymph node, in a slow-release formulation 
(Montanide).
Results: 
The delivery of anti-CD40 monoclonal antibody, formulated in slow release 
Montanide ISA-51, reprograms CTLs by inducing local but not systemic 
dendritic cell activation, resulting in effective tumor-specific CTL responses, 
which eradicate local and distant tumors. Adverse side-effects, assayed by organ 
histology and liver enzymes in the blood, were much lower upon local anti-CD40 
antibody delivery as compared to systemic administration. The local delivery 
of anti-CD40 antibody activates only CTLs against antigens presented in the 
tumor-draining area, because unrelated distant tumors expressing different 
tumor antigens were not eradicated. 
Conclusions: 
These results establish a novel therapeutic principle that local delivery and slow 
release of agonistic anti-CD40 antibody to the tumor-draining area effectively 
activates local tumor-specific CD8 T cells to become systemic effectors without 
causing systemic toxicity or non-specific CTL activation. These findings have 
important implications for the use of anti-CD40 therapies in patients.
Statement of translational relevance:
Systemic delivery of agonistic anti-CD40 antibodies induces good anti-tumor 
immune responses in pre-clinical models but dose-limiting toxicity hampers 
clinical success. We have used a novel delivery system based on the slow-release 
agent Montanide ISA-51 to distribute agonistic CD40 antibody in the lymphoid 
drainage area of the tumor, which stimulates local but not systemic dendritic 
cells. Local dendritic cell activation results in a robust systemic anti-tumor 
CD8 T-cell response and both local and distant tumor eradication without the 
side effects associated with the standard systemic administration of anti-CD40 
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antibody. These results indicate an important novel delivery platform for the use 
of anti-CD40 antibody and conceivably other immune stimulatory therapies in 
cancer patients.
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Introduction
CD8+ T cells (cytotoxic T lymphocytes (CTLs)) recognize and kill specific target 
cells based on their T cell receptors (TCRs) that are selected to recognize antigens 
presented by MHC class I molecules [1]. Since many tumors express aberrant 
antigens, CD8+ T cells have the potential to eradicate these tumors [2-4]. The 
induction of anti-tumor T-cell priming, however, is often ineffective. One of the 
reasons for this phenomenon is that dendritic cells (DCs), which cross-present 
the tumor antigens in tumor-draining lymph nodes are poorly activated due 
to a lack of danger signals and insufficient CD4+ T-cell help [5-8]. Methods to 
effectively activate those DCs and thereby enhance the anti-tumor CTL response 
may thus provide significant improvement for the treatment of cancer. 
The tumor necrosis factor receptor (TNFR) family member CD40 is a stimulatory 
molecule and constitutively expressed on a large variety of cells, including 
DCs, B cells, macrophages, and endothelial cells [9]. Engagement of CD40 on 
DCs provides potent maturation signals leading to improved T-cell mediated 
tumor rejection [10, 11]. Several in vivo studies have shown that CD40 ligation 
by systemically delivered agonistic antibodies can induce robust anti-tumor 
immune responses, either as monotherapy or in combination with TLR ligands, 
cytokines and chemotherapy, indicating clinical potential. [12-17]. However, 
serious side effects of treatment with agonistic CD40 antibodies in the clinic 
have been reported, which include cytokine release syndrome and liver function 
abnormalities [18]. Adverse effects have also been reported for several other 
therapies that are based on antibodies that mediate systemic immune activation, 
such as CTLA-4 blocking antibodies and agonistic anti-CD28 antibodies [18-21].
Previously, we have shown that tumor antigens are predominantly presented 
by DCs in the tumor-draining lymph node, which results in detectable amounts 
of tumor-specific CD8+ T cells trapped within that lymph node [22, 23]. We 
hypothesize that local tumor antigen presenting DCs are the main target for 
agonistic anti-CD40 antibodies. To investigate the possibility to more specifically 
target the antibody treatment to the tumor-draining area and prevent systemic 
immune activation and toxicity, we investigated in the present study the 
utilization of local antibody injection in a slow release formulation. We found that 
local injection of agonistic CD40 antibody is more effective in enhancing the anti-
tumor response than a similar dose given systemically and that a slow-release 
formulation is attractive to use in clinical settings since it resulted in substantial 
decrease in toxicity compared to systemic delivery. Importantly, although the 
treatment is strictly local, the tumor-specific T cells spread systemically and 
eradicate both local and distant related tumors. 
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Material and Methods
Mice
C57BL/6 mice were purchased from The Jackson Laboratory. C57BL/6 Kh (B6, 
H-2b) were bred at the LUMC animal facility. The experiments were approved by 
the animal experimental committee of the University of Leiden.
Tumor experiments
Mouse embryonic cells transformed by the early region 1A of human adenovirus 
type 5 (Ad5E1A) plus EJ-ras (AR6) [24] were cultured in Iscove’s modified 
Dulbecco’s medium (IMDM): (BioWhittaker, Verviers, Belgium) supplemented 
with 4% FCS, 50 µM 2-mercaptoethanol and 100 IU/ml penicillin/streptavidin. 
EG7 tumor cells expressing the full-length OVA antigen were cultured in 
IMDM (Invitrogen Life Technologies, Rockville, MD) supplemented with 8% v/v 
FBS (Greiner), 50 µM 2-ME, 2 mM glutamine, 100 IU/mL penicillin (complete 
medium) supplemented with 400 µg/mL G418 (Gibco) [25]. AR6 tumor cells do 
not express CD40 and EG7 tumor cells express low levels of CD40 on their cell 
surface.
The AR6 (E1A expressing) tumor cells (7.5 x 106) were injected s.c. into 7-13 
week-old male mice in 200 µl of PBS. Treatment was started 8-14 days after 
tumor inoculation, when palpable tumors were present. EG7 tumor cells (1 x 
106) were injected s.c. into 7-13 week old male mice in 200 µl of PBS. Treatment 
was started 3 days later. Secondary tumors were injected one day before start of 
treatment. Tumor size was measured twice weekly in three dimensions and mice 
were killed when tumor size exceeded 1 cm3.
Flow cytometry
Single-cell suspension of blood and spleens, after erythrocyte lysis, and lymph 
nodes were stained with anti-CD8a (clone 53-6.7), anti-CD62L (clone MEL14), 
anti-CD11c (clone HL3), anti-CD70 (clone FR70), CD90.1 (Thy1.1; clone OX-7), 
CD19 (clone 1D3) and CD3ε (clone 145-2C11) all from BD Bioscience, anti-KLRG1 
(clone 2F1) from Southern Biotech, and E1A234-243-loaded H-2Db tetramers and 
OVA257-264–loaded H-2Kb tetramers.
Agonistic CD40 antibody treatment
The FGK-45 hybridoma cells producing an agonistic anti-CD40 Ab were 
provided by A. Rolink (Basel Institute for Immunology, Basel, Switzerland) [26]. 
Hybridomas were cultured in Protein Free Hybridoma Medium (Gibco), and 
mAbs were purified using a Protein G column. FGK-45 antibody contained <2 
IU/mg endotoxin. Mice treated with high dose, systemic treatment were injected 
with 100 micrograms of antibody in PBS intravenously, on three consecutive 
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days. Montanide/antibody emulsions were made by mixing different dosages of 
antibody in PBS 1:1 with montanide (Montanide ISA-51, Seppic), and vortexing 
for 30 minutes. 
Serum analyses
Serum samples were taken from mice at several time points after treatment. 
ALAT and ASAT analyses were performed by the department of Clinical 
Chemistry of the LUMC hospital according to standard protocols. Anti-CD40 
antibody concentrations were analyzed by ELISA with anti-rat antibodies (BD 
bioscience).
Histology
Liver, lung and kidney were isolated from mice at several time points after 
treatment. Tissues were fixed with formalin and embedded in paraffin, 4 µm 
sections were made and sections were stained with H&E staining. Images were 
captured using a Zeiss Axioskop 40 microscope and processed using axiovision 
AC software. 
In vivo cytotoxicity assay
In vivo cytotoxicity was determined using as target cells Thy1.1+ splenocytes. 
Target cells were labeled with 5 µM CFSE and pulsed with E1A234-243, 
SGPSNTPPEI peptide (0.5 µg/mL for 90 min at 37°C) or labeled with 0.5 µM 
CFSE and pulsed with control peptide. Target cells were mixed in a 1:1 ratio of 
E1A-pulsed to control cells and injected i.v. (5 × 106 cells of each population) into 
naïve and tumor-bearing mice, 9 days after being treated with low dose anti-
CD40 in montanide, high dose systemic anti-CD40 or no treatment. Three days 
after injection of the target cells, spleens were isolated and the number of CFSEhi 
and control CFSElo Thy1.1+ target cells was determined by flow cytometry. The 
percentage of specific killing is calculated as follows: [1 - (ratio tumorbearing/
ratio naive)] × 100%. Ratio is defined as the number of E1A CFSEhi target cells/
number of control CFSElo target cells.
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Results:
Local treatment with a low dose of agonistic anti-CD40 antibody in a 
slow-release formulation combines effective treatment and decreased 
toxicity. In order to determine the most optimal anti-tumor treatment 
with agonistic anti-CD40 antibodies, we compared the effects of different 
administration methods and antibody dosage on both tumor eradication efficacy 
and toxicity in organs such as liver. Mice were inoculated subcutaneously with 
adenovirus protein E1A expressing tumor cells (AR6), previously described to be 
eradicated by CD8+ T-cells [24], which grew into palpable tumors over 10 days. 
Subsequently, these tumor-bearing mice were treated with 1) a standard dose 
(100 ug) of agonistic anti-CD40 antibody delivered systemically during three 
consecutive days, 2) a low dose (30 ug) delivered systemically (i.v.), 3) a low 
dose delivered locally (s.c.) in saline, or 4) a low dose delivered locally in a slow-
release formulation (Montanide-ISA-51) [27]. The subcutaneous treatments 
were injected in the area between the tumor and the tumor-draining inguinal 
lymph node. As is shown in figure 1A, mice receiving local treatment either 
in Montanide or in saline displayed an equal percentage of tumor eradication 
and survival and both of these treatments are equally effective in clearing the 
tumor as the standard systemic i.v. treatment. The low dose i.v. injected group, 
however, showed no evidence of tumor growth reduction, and as a consequence 
most mice in this group did not survive. These results indicate that a low dose of 
anti-CD40 can be equally effective as a high dose to eradicate tumors provided 
that it is injected closely to the tumor and/or tumor-draining lymph node.
We assessed the toxicity caused by the aforementioned treatments by analyzing 
the liver enzymes ALAT and ASAT, known to be indicative for tissue damage 
[28], in serum one day after antibody treatment. The levels of these liver enzymes 
were substantially higher in the group treated with systemically administered 
CD40 antibody as compared to local treatments. Remarkably, toxic effects of 
local treatment were further decreased to base-line levels when CD40 antibody 
was administered in the slow release (Montanide) formulation (figure 1B). This 
correlated with concentration of anti-CD40 antibody found in the serum of these 
mice one day after treatment (Supplemental Figure 1). 
Comparison of the kinetics of the ALAT and ASAT levels between the low-dose 
plus slow-release treatment and the standard systemic high-dose treatment, 
showed that these liver enzymes were elevated especially during the first days 
after systemic treatment and suggest that tissue damage follows (Figure 1C). 
The administration of a high dose (150 µg) of anti-CD40 antibody in a slow 
release formulation causes also liver inflammation as determined by liver 
enzyme elevation (data not shown). Histological analysis performed at several 
time-points after treatment, showed that indeed damage to the liver was evident 
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(Figure 1D). At day 3 post-treatment, the livers from mice that received systemic 
high-dose anti-CD40 treatment were severely affected. Livers displayed 
lobular foci with a minor component of portal inflammation. The lobular foci 
of inflammation consisted of lymphocytes (predominantly CD3+), plasma cells 
and histiocytes (including F4/80+ macrophages) (data not shown). At day 7 post-
treatment, lobular inflammations had mostly subsided but portal inflammation 
(with lymphocytes) was enhanced. 
Figure 1: Low dose local treatment with anti-CD40 gives lower toxicity then high dose systemic 
treatment.
Tumor-bearing mice were treated with different dosages and administration methods of anti-CD40 agonist 
antibody, 8 days after tumor inoculation. Tumor-survival after administration of 30 µg of antibody either 
intravenously, subcutaneously in saline or in montanide was compared to the standard protocol of 3 subsequent 
high dose systemic injection of antibody. 8 mice per group, representative of 3 experiments (A). Liver enzyme 
concentrations in serum, 24 hours after treatment with different administration methods of 30 µg of antibody. 
Student T-test revealed significant differences between groups. (IV vs montanide p= 0.002 and 0.001 for ALAT 
and ASAT respectively, montanide vs saline p=0.004 and 0.09 for ALAT and ASAT respectively) 4 mice per group, 
representative of 2 experiments (B). Liver enzymes in serum in time after treatment with 30 µg of antibody 
subcutaneously in montanide, compared to standard protocol. 7 mice per group, representative of two experiments 
(C). Histological sections of liver at day 1, 3 and 7 after treatment with 30 µg of antibody subcutaneously in 
montanide, compared to standard protocol. Representative sections of groups of 3 mice (D).
In contrast, livers from mice receiving a low dose anti-CD40 antibody in 
Montanide displayed much less extensive signs of liver damage on day 3 post-
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treatment and on day 7 only remnant signs of inflammation were visible. The 
lungs and kidneys in mice that were treated with a high dose systemic anti-
CD40 also showed more severe damage, as evidenced by lymphocytic infiltration, 
compared to these organs in mice that had received low dose local treatment (data 
not shown). Together these data show that a lower dose and local subcutaneous 
injection of CD40 agonistic antibody is sufficient for tumor eradication and 
that this treatment, if applied in a slow-release formulation, caused the least 
immune-mediated toxicity.
Figure 2 Low dose local treatment gives similar anti-tumor response as standard treatment, and is a 
strictly local treatment.
Survival and tumor-growth of tumor-bearing mice after treatment with 30 µg of anti-CD40 agonist antibody in 
montanide, subcutaneously compared to standard protocol, and compared to injection into the contralateral flank, 
8 days after tumor inoculation. Data presented as cumulative survival from two independent experiments, 12 or 
13 mice per group. Kaplan-Meier test revealed a significant difference between local treatment and no treatment, 
and local treatment and contralateral treatment (p=0.002 and p=0.03 respectively) (A). Data presented as tumor-
growth in each mouse, 6 or 7 mice per group, number of mice that died of tumor-burden indicated in upper left-hand 
corner. Representative of three experiments (B).
Local delivery of low-dose anti-CD40 in Montanide is essential for 
therapeutic efficacy.
 To examine whether a low dose anti-CD40 therapy in a slow-release formulation 
(Montanide) is only effective to induce an anti-tumor response when delivered 
close to the tumor, we tested whether contralateral injection could also induce 
tumor eradication. As is shown in Figure 2, tumor growth and survival of mice 
treated with low dose anti-CD40 in Montanide close to the tumor was comparable 
to those of mice treated with high dose systemic anti-CD40. Mice treated with 
low dose Montanide- formulated antibody in the contralateral flank, however, did 
not eradicate the tumor (Figure 2 A, B). When tumor-bearing mice were treated 
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with a high dose of anti-CD40 in Montanide (150 microgram), either close to the 
tumor, or in the opposite flank (contralateral flank) the anti-tumor effects were 
similar, indicating that only a low dose is confined in its therapeutic action to 
the tumor-draining area (Supplemental Figure 2A). Mice locally injected with 
a Montanide depot lacking anti-CD40 antibody, did not show any anti-tumor 
effect (Supplemental Figure 2B). These data demonstrate that the therapeutic 
effect of low dose agonistic CD40 antibody treatment in Montanide was strictly 











































































































































































































































































































Figure 3 Systemic CTL 
response after local, low 
dose, montanide treatment 
with anti-CD40 antibody.
Quantity and functionality of 
the anti-tumor CTL response 
in blood after local, low dose, 
montanide treatment with 
anti-CD40 agonist antibody, 
compared to standard 
treatment. 8 days after start 
of treatment, CD8+, tetramer+ 
T-cells were analyzed in 
blood. Student T-test revealed 
significant differences 
between no treatment and low 
dose, montanide treatment 
groups (p= 0.04). (A) Nine 
days after start of treatment 
specific lysis was determined. 
Mann-whitney test revealed 
significant differences between 
no treatment and low dose, 
montanide treatment groups 
(p<0.0001). Two experiments 
pooled, 9 mice per group. (B) 
Phenotypic analyses of tumor-
specific CTLs in tumor-draining 
lymph nodes and spleen, 10 
days after start of treatment. 
Mice were sacrificed and CD8+, 
tetramer+ cells were analyzed 
in tumor-draining LN and 
spleen for CD62L and KLRG-
1 expression. Upper panels 
display representative samples 
of CD8 and tetramer staining of 
tumor-draining lymph nodes. 
Lower panels show CD62L 
and KLRG-1 expression of 
CD8+ cells (in grey) and CD8+, 
tetramer+ cells (in black) in tumor-draining lymph nodes (C). Bar graphs indicate mean and SEM of CD62L low 
(grey) and CD62L low/KLRG-1 high cells (black) of CD8+ and tetramer+ cells in tumor-draining lymph node (left 
panel) and spleen (right panel) of 4 mice per group (D). One representative experiment of two.
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Local treatment with low dose CD40 agonist causes systemic CTL 
responses equal to high dose systemic treatment
The induction of anti-tumor eradication by local treatment with anti-CD40 in 
the vicinity of a tumor could be explained by the activation of local CD8 T cells to 
become systemic effector CTL. In order to examine this possibility, we analyzed 
tumor-specific CD8+ T cells in secondary lymphoid organs of treated and untreated 
mice. The anti-tumor CTL response was clearly detectable systemically in blood 
at day 8 post-treatment with both the standard high dose i.v. protocol and the 
locally administered low dose treatment in Montanide, in comparison to non-
treated mice, indicating that the local treatment is capable to induce a potent 
systemic CD8 T cell response (Figure 3A). In order to determine the functionality 
of these tetramer-positive CTLs, we performed an in vivo cytotoxicity assay. 
Specific lysis of target cells in vivo correlated with the presence of tumor-specific 
(tetramer+) CD8+ T cells in blood. Both treated groups of mice specifically killed 
target cells loaded with the tumor antigen to a similar extent, in contrast to the 
non-treated group (Figure 3B).
Figure 4 DC activation 
in tumor-draining 
lymph node after 
local treatment
CD70 expression on 
CD11c high cells in 
tumor-draining and 
non-draining lymph 
nodes of tumor-bearing 
mice, non-treated, high 
systemic dose treated 
of low dose, montanide 
treated. 4 mice per group, 
one representative 
experiment of two. 
We next investigated phenotypic effects of these treatments on the cell-surface 
of tumor-specific CTLs in spleen and lymph node. By examining effector T 
cell markers CD62L and KLRG-1 on tetramer+ T cells, we could determine 
whether the different administration routes activated tumor-specific T-cells in 
a qualitatively different manner. The down-modulation of the homing receptor 
CD62L and the up-regulation of the Killer cell lectin-like receptor G1 (KLRG-
1, marker for effector cells) were similar in tumor-draining lymph nodes and 
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spleens after either high dose systemic or low dose local treatments (Figure 3C, 
D). In non-treated mice, however, the KLRG1 expression on tetramer-positive 
CD8+ T cells was lower in the draining lymph nodes. The tumor-specific CTL 
response in this group could not be detected systemically in blood and spleen. 
To determine the effects of CD40-mediated DC maturation in tumor draining 
versus non-draining lymph nodes of tumor-bearing mice, we measured the 
expression of the TNF ligand family member CD70 on the cell surface of DCs 
[29-31]. In mice that were treated intravenously, DCs in both tumor-draining 
and non-draining lymph nodes showed high expression of cell surface CD70 
which indicates systemic activation of DCs (Figure 4). In contrast, the CD70 
expression on the cell-surface of DCs in mice that received local treatment in 
Montanide formulation was strongly up-regulated in tumor-draining but not 
non-draining lymph nodes. Similar results were obtained with staining of the 
costimulatory molecule CD80 (B7.1). Treating mice with Montanide alone or 
Montanide containing control antibody did not mature DC in the LN (data not 
shown). Thus, predominantly the DCs in the draining lymph node (LN) of mice 
treated with the low dose of anti-CD40 in Montanide are activated, whereas the 
DCs in lymphoid organs distant from the tumor-draining area remain immature. 
Local treatment can eradicate a distant tumor.
We hypothesized that even though an antibody treatment is delivered locally, 
it could still be effective in eradicating metastasized (secondary) related 
(presenting the same tumor antigens) tumors due to the induction of a systemic 
CTL response. To test this hypothesis, we used a model for metastasis in which 
we inoculated groups of mice subcutaneously with tumor cells in the right 
flank (first tumor), except for one group which was not inoculated. Eight days 
later, when tumors in the right flank were palpable, we inoculated all groups 
subcutaneously with tumor cells in the left flank (second tumor). Mice were 
treated the next day, either with high dose anti-CD40 antibodies i.v., or with 
low-dose anti-CD40 antibody in Montanide either injected locally close to the 
palpable primary tumor in the right flank or injected in the right flank where 
no tumor cells were inoculated. Tumor growth of tumors on both flanks was 
measured regularly and the anti-tumor CTL response was analyzed in blood. As 
depicted in Figure 5, tumor-specific CD8+ T-cells were observed in the blood of the 
systemically treated group as well as in the blood of the group that was treated 
locally near the right flank tumor. Tumor-specific CTLs were not demonstrable 
in the blood of mice that were treated subcutaneously in the right flank and were 
not inoculated with tumor cells at this site. Consistent with these findings, the 
growth of the secondary tumor on the left flank is strongly inhibited in the groups 
treated with systemic high-dose anti-CD40 antibody and in the group treated 
with the low-dose of anti-CD40 antibody in Montanide, which was administered 
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close to the tumor in the right flank (Figure 5C,D; groups II and III). Mice that 
received no primary tumor and were injected with the low-dose anti-CD40 in the 
right flank succumbed to rapid outgrowth of the secondary tumor (Figure 5B, C; 
group IV). Taken together, these studies show that local treatment with anti-
CD40 antibody in a slow-release formulation is effective in prompting systemic 
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Figure 5 Local treatment can eradicate a distant tumor.
Eradication of secondary tumor by tumor-specific CTLs activated by local treatment with low dose anti-CD40 
in montanide, compared to standard treatment. Data are presented as cumulative survival (10 mice per group), 
representative experiment of two. Kaplan-Meier test reveals differences between no treatment group and low dose, 
montanide group (p= 0.05) and between no treatment and high dose IV (p= 0.05) and between low dose, montanide 
and low dose, montanide contralateral (p= 0.1). Tumor growth was measured and data are presented for each 
independent mouse, primary (red dotted line) and secondary tumor (black line). Between brackets is noted how 
many mice were tumor free at the end of the experiment. (C). Tumor inoculation and treatment scheme (D)
Local treatment of primary tumors is capable of eradicating distant 
secondary tumors, but not unrelated tumors. 
In order to substantiate that local treatment activates exclusively specific anti-
tumor CTL responses that eradicate related (but not unrelated) distant tumors, 
thereby avoiding systemic T cell activation which may cause unwanted side 
effects such as 
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immune pathology and auto-immunity, we decided to employ a combination of 
two unrelated tumors (AR6, mouse embryonic cell line expressing adenovirus 
protein E1A and EG7 lymphoma expressing OVA protein) in one experimental 
model. By utilizing these tumor cells as first and/or second tumors, we were able 
to investigate the tumor-clearing potential of CTLs activated by local anti-CD40 
treatment and the role of tumor-antigens presented at the local injection site 
(see scheme in Figure 6). 
Treatment with anti-CD40 
in montanide
Primary tumorSecondary tumor
Treatment with anti-CD40 
in montanide
Primary tumorSecondary tumor
Primary tumor Secondary tumor
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Figure 6 Tumor-eradicating response is activated by locally available tumor-antigen.
Eradication of secondary tumor by tumor-specific CTL activated by local treatment with low dose anti-CD40 in 
montanide. Dependence of tumor-eradicating capacity of CTL on locally available tumor-antigen. Tumor growth 
was measured and data are presented for each independent mouse, primary (red dotted line) and secondary tumor 
(black line). Between brackets is noted how many mice were tumor free at the end of the experiment. (A). Tumor 
inoculation and treatment scheme (B). Specific CTL response in blood at day 11 after treatment (C). 12 mice per 
group, one representative experiment of two.
First, we established that local anti-CD40 treatment was successful in 
generating tumor-specific CTL responses and tumor eradication following EG7 
tumor challenge (data not shown). Next, we challenged mice with two unrelated 
tumors according to scheme (fig 6B). We found that the related secondary 
tumor was completely eradicated when a specific CTL response was activated 
by the primary tumor (Figure 6, group I), but grew out when unrelated tumors 
(expressing different tumor antigens than the second tumor) were employed as 
a first tumor (Figure 6, group II). In mice that received EG7 as a primary tumor, 
and were injected with both AR6 and EG7 tumor cells as distant tumors (Figure 
6, group III), the outgrowing tumor was a solitary AR6 tumor as determined 
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by histology (suppl. Fig. 3). In all cases tumor eradication was accompanied by 
a systemic CTL response specific for the antigen present at the treatment site 
(Fig 6C). These results indicate that local treatment with anti-CD40 activates 
CTLs specific for tumor antigens that are presented in the vicinity of the local 
treatment area and in case of metastasis of related tumors these CTLs possess 
potent systemic anti-tumor cytotoxicity. 
Discussion
We here report a novel administration method for anti-CD40 agonistic antibody 
as a monotherapy against immunogenic tumors. By using a slow-release agent 
(Montanide) to deliver the antibody close to the tumor-draining lymph node, we 
were able to induce activation of tumor-specific CTLs as defined by expansion 
and differentiation into potent effectors as well as effusion to the systemic 
circulation. Importantly, we were also able to reduce the adverse side effects, 
including liver toxicity as observed with I.V. injections. This treatment is only 
effective when injected close to the tumor, but is capable of activating a systemic 
CTL response that can eradicate tumors at distant locations. The systemic CTL 
response is specific for tumor antigens present at the site of treatment, which 
avoids unwanted systemic T cell activation and its associated detrimental side 
effects such as immune pathology and auto-immunity.
Previously, we reported that both NK cells and CD4+ T cells are not critically 
involved in the anti-tumor effect of anti-CD40 antibody treatment against our 
tumor-model but that cytotoxic CD8+ T cells play a crucial role [10, 22]. Together 
with the knowledge that the tumor antigen was presented mainly by CD11c+ 
cells in the tumor-draining lymph node [22], this lead us to focus on targeting 
the CD40 activating antibody to these organs in order to activate the tumor-
antigen presenting APC, which, in their turn, activate the tumor-specific CTL. 
We hypothesize that activation of DCs in the lymph node is instrumental in 
the systemic anti-tumor response caused by our local treatment. Our finding 
that DCs in the tumor draining LN after local treatment express CD70 whereas 
the DCs in non-draining LN do not, underlines the local induction of immune 
responses, which nevertheless induce a systemic anti-tumor CTL response that 
can eradicate distant related tumors. 
Considering the presence of CD40 molecules on numerous cell types distributed 
through the body and their role in various processes, it is not unexpected that 
toxicity caused by systemic treatment with an agonist antibody against CD40 
can occur but thus far this has been a largely ignored phenomenon in preclinical 
animal models. In addition, some groups reported that very high dosages of anti-
CD40 induce deleterious effects on CD4 and CD8 T cell responses [32, 33]. 
Several studies have been published on the effects of targeting the tumor or the 
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tumor-draining lymph node, using tumor-specific antibodies or cellular vaccines 
producing cytokines and antibodies [34-37]. Although these studies have 
successful outcomes, they are all technically challenging and require knowledge 
regarding tumor-specificity. The method of administration as reported here is 
relatively straightforward and applicable to different types of immunogenic 
tumors. Jackaman et al. and we have previously shown that intratumoral 
injections of anti-CD40 led to eradication of local and distal tumors. However, 
these studies have not addressed the toxicity as described here. [38] By using 
a slow-release delivery method to target anti-CD40 agonistic antibody to the 
tumor-draining area, we were able to drastically decrease the dose needed for 
effective anti-tumor CTL activation and significantly reduce antibody-mediated 
side-effects. We found that toxicity, as measured by serum liver enzyme levels, 
in mice after systemic injection reaches plateau levels already at an injected 
dose of 10 mg, whereas anti-tumor CTL activation is not effective at this dose, or 
even at 30 mg. We therefore conclude that systemic injection of agonistic CD40 
antibody has no proper therapeutic window (unpublished observations). Our 
findings have important implications for the use of anti-CD40 in the clinic, as 
CD40 agonist antibody therapy in a clinical trial was found to be associated with 
biological and anti-tumor activity but was hampered by dose-limiting toxicity 
[18]. Therefore, we propose the use of our treatment method in a clinical trial in 
order to reduce toxicity and achieve full anti-tumor efficacy. 
Some studies which describe the use of anti-CD40 as an immunotherapy against 
tumors conclude that monotherapy is not sufficient for tumor-eradication but 
that this treatment has to be combined with cytokines, TLR ligand signaling or 
chemotherapy [13-15, 39]. We agree that anti-CD40 monotherapy as described 
in this study is not always capable of tumor eradication and that the use of 
combinatorial treatments will be beneficial and we propose that our superior 
administration method (i.e. delivery of a low dose agonistic CD40 antibody in 
a slow-release formulation in the tumor-draining area) is also valuable when 
combining anti-CD40 treatment with other agents.  
In conclusion, this study shows that precision guiding of tumor-specific CTL 
from tumor-draining lymph nodes by local delivery of immunostimulants to 
DCs cross-presenting tumor antigen constitutes a novel way to elicit systemic 
therapeutic CTL responses. This approach lends itself without difficulty to 
clinical exploratory trials, because Montanide–ISA-51 delivery is safe in human 
individuals [40] and because appropriate agonistic antibodies against human 
CD40 are available [18].
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Abstract
Blockade of CTLA-4 by antibodies has potentiated anti-tumor T cell responses 
in both pre-clinical models and clinical trials. However, treatment with CTLA-
4 blocking antibodies is associated with auto-immune and inflammatory side-
effects. In this study, we propose a novel administration method for CTLA-4 
blocking antibodies. By injecting the antibodies in a subcutaneous slow-release 
delivery formulation close to a tumor-draining lymph node, we show that an 
eightfold lower dose of antibody is as effective in activating a tumor-eradicating T 
cell response as systemic delivery. The significantly decreased levels of antibody 
in the serum cause less adverse events and reduce the risk of auto-immunity. 
The main target and effector cells in the tumor-model described here are CD8+ T 
cells, whereas CD4+ T cells do not play a prominent role in the antibody-mediated 
tumor eradicating effect. These results call for investigation of a similar delivery 
system of CTLA-4 blocking antibody in the clinic to reduce toxic side effects. 
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Introduction
T cell mediated immunotherapy holds great potential for the treatment of human 
malignancies. A crucial element of this therapy is the ability of CD8+ T cells 
(cytotoxic T lymphocytes (CTLs)) to recognize and kill tumor cells that express 
tumor associated antigens [1;2]. Different types of tumor-associated antigens 
can be targeted such as those arising through mutations (e.g. p53, BCR-ABL 
and RAS), differentiation antigens (Tyrosinase, gp100, MART-1, Mucin), viral 
antigens, (HPV E6/E7, EBNA-1) and overexpressed antigens (WT, MDM2, HER-
2/neu). Therapeutic interventions aimed at enhancing the efficacy of anti-tumor 
CD8+ T cell responses are necessary to achieve clinical efficacy.
Effective priming of T cells requires antigenic stimulation of the T cell receptor 
in conjunction with costimulatory signals. B7.1 (CD80) and B7.2 (CD86) are 
costimulatory molecules expressed on antigen presenting cells (APCs), which 
bind to CD28 and CTLA-4 on T cells [3;4]. CD28 is constitutively expressed on T 
cells and provides essential costimulatory signals, whereas CTLA-4 is inducibly 
upregulated on convential T cells and inhibits the T cells activation. Several 
mechanisms of CTLA-4 inhibition have been proposed. CTLA-4 has been shown 
to outcompete CD28 for B7 ligation, inhibiting the positive activation effect of 
CD28. This was established in cells with CTLA-4 molecules containing non-
functional cytoplasmic tails. These cells were still able to inhibit T cell responses 
[5-7]. Recent studies described that this result could also be due to back-signaling 
to B7, described to induce IDO, a metabolic enzyme expressed on APC that 
catabolises tryptophan, leading to starvation of T cells [8]. This latter finding 
has been implicated to be one of the mechanism through which T regulatory cells 
suppress T cell responses via APCs, as T regulatory cells constitutively express 
CTLA-4, which is important for their suppressive phenotype [9]. And lastly, 
CTLA-4 signaling has been shown to be responsible for reversing the TCR-stop; 
effectively ending the process of activation by detachment of the immunological 
synapse and increased T cell motility [10;11]. 
Blocking the interaction of CTLA-4 with B7.1 and B7.2 has been demonstrated 
to improve antitumor T cell responses in pre-clinical tumor models and in 
cancer patients [12-16]. Recently,  promising clinical results have been obtained 
with CTLA-4 blockade in melanoma patients that have led to approval by the 
FDA for treatment of advanced melanoma [17]. However, CTLA-4 treatment 
is accompanied by auto-immune and inflammatory side effects such as colitis, 
dermatitis, uveïtis and hypophysitis. 
Previously, we have shown that local delivery of agonistic antibody against CD40 
in the tumor-draining area was equally effective in activating tumor-specific 
CD8+ T cell responses leading to tumor eradication, with strongly decreased 
treatment-induced toxicity  in comparison with systemic administration [18]. 
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In this study we show that local injection of a CTLA-4 blocking antibody in the 
slow-release formulation Montanide ISA-51 in tumor bearing mice leads to an 
effective anti-tumor CD8+ T cell response and tumor eradication, while levels 
of systemic antibody in serum remain low. The treatment was dependent on 
CD8+ T cells whereas CD4+ T cells do not play a major role. Thus, local CTLA-4 




C57BL/6 mice were purchased from The Jackson Laboratory. The experiments 
were approved by the Animal Experimental Committee of the University of 
Leiden.
Tumor experiments
MC-38 cells expressing ovalbumin (MC38-ova) [19] were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM): (BioWhittaker, Verviers, Belgium) 
supplemented with 4% FCS, 50 µM 2-mercaptoethanol and 100 IU/ml penicillin/
streptomycin. The tumor cells (0.5 x 106) were injected s.c. into 8-12 week-old 
female mice in 200 µl of PBS. Treatment was started 7-10 days after tumor 
inoculation, when palpable tumors were present. Mice were sacrificed when 
tumors reached a size of 1000 mm3 to avoid unnecessary suffering.
Flow cytometry
Single-cell suspensions of spleens underwent erythrocyte lysis, and were 
subsequently stained with CD8a (clone 53-6.7), CD4 (clone RM4-5), and CD3ε 
(clone 145-2C11) mAbs (BD Bioscience), and OVA257-264–loaded H-2Kb tetramers. 
All stained cells were analyzed on a FACScalibur (Becton Dickinson) and data 
analysis was performed with Flowjo (treestar).
Antibody treatment
 Hybridoma cells producing a CTLA-4 blocking Ab clone 9H10 [5], a depleting 
CD8 mAb (clone 2.43) or a depleting CD4 mAb (clone GK1.5) were cultured 
in Protein Free Hybridoma Medium (Gibco), and mAbs were purified using a 
Protein G column. Mice treated systemically with CTLA-4 blocking mAb received 
200 micrograms mAb (high dose) in PBS intraperitoneally on day 0 and day 3 
or received 50 micrograms mAb (low dose) at day 0. Mice treated locally with 
a low dose CTLA-4 blocking mAb received 50 micrograms mAb in montanide, 
subcutaneously on day 0. Montanide/ 9H10 antibody emulsions were made by 
mixing antibody in PBS 1:1 with montanide (Montanide ISA-51, Seppic), and 
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vortexing for 30 minutes. To deplete CD8+ or CD4+ T cells mice received an i.p. 
administration of 100 microgram anti-CD4 or anti-CD8 on day -1, 2, 7, 14, 21 
after tumor inoculation. The efficiency of T cell subset depletion was measured 
by staining of blood lymphocytes for cell surface CD4 and CD8 (using non-
competitive mAbs) and indicated a consistent depletion of >98% of the total T 
cell populations. All control mice received in parallel similar amounts of isotype 
control rat IgG. 
Serum analyses
Serum samples were taken from mice at several time points after CTLA-
4 treatment. ALT and AST analyses were performed by the department of 
Clinical Chemistry of the LUMC hospital according to standard protocols. Auto 
antibodies were analyzed in serum with the Anti-Nuclear Antibodies-ELISA kit 
(US Biological, Swampscott, MA, USA) according to manufacturer’s instructions. 
CTLA-4 blocking antibodies levels in serum were detected in an ELISA using 
purified and biotin-labeled mouse anti-hamster antibodies (clone 192-1) from BD 
bioscience.
Results
Tumor eradication by local treatment with a low dose of CTLA-4 
blocking antibody is equally effective as high dose systemic treatment.
We previously described that a low dose of agonistic CD40 antibody delivered 
locally in a slow-release formulation (Montanide-ISA-51) was very effective in 
inducing systemic anti-tumor immunity without strong systemic side-effects. 
We hypothesized that this administration technique would also be applicable 
to other immune modulating antibodies, such as CTLA-4 blocking antibody. To 
verify this, mice were inoculated subcutaneously with MC-38-ova tumor cells 
(murine coloncarcinoma cells expressing ovalbumin in the cytoplasm). Seven 
days after tumor inoculation, when palpable tumors were present, treatment 
was started. Mice underwent either the standard systemic treatment of CTLA-
4 blocking antibody (2 injections of 200 microgram intraperitoneally) or were 
treated locally by receiving one injection of 50 microgram in montanide close 
to the tumor. Both the high dose systemic and low dose local treatment with 
CTLA-4 blocking antibody was able to induce tumor eradication as compared to 
non-treated mice (Figure 1a and b). Mice treated with a systemic administration 
of the low dose, 50 microgram, were not able to clear the tumor, indicating that 
this dose is only effective when delivered into the tumor-draining area (Figure 
1c). To determine whether tumor eradication correlated with enhanced tumor-
specific T cell responses we analyzed the magnitude of the CD8+ T cell response 
in tumor-bearing mice treated with CTLA-4 blocking antibody. The tumor-
specific CD8+ T cell response in the spleen and blood, as analyzed by tetramer 
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staining, was enhanced in mice that underwent either the high systemic dose 
or the low dose local treatment as compared to untreated mice (Figure 1d and 
data not shown). Thus, local low dose of blocking CTLA-4 treatment is similar in 
tumor-eradicating capabilities and induction of tumor specific CTL responses as 
high dose systemic treatment.
Fig. 1 Local treatment with a low dose of CTLA-4 blocking antibody induces effective tumor eradication. Mice 
bearing palpable MC-38-ova tumors were treated with two intraperitoneal injections with high dose (2 x 200 µg) of 
CTLA-4 blocking antibody (standard treatment), or one subcutaneous, local, injection with low dose (50 µg) CTLA-
4 blocking antibody in slow-release agent Montanide ISA51. Tumor growth was measured at regular intervals. a 
Data presented as tumor growth in each mouse, 10 mice per group. b Survival curve. Shown are pooled data of 4 
independent experiments, 32 mice per group. Kaplan-Meier test revealed significant differences between non-
treated group and local treated group or intraperitoneal treated group, 0.002 (**) and 0.0002 (***) respectively. c 
Survival curve of mice treated with either high dose (2 x 200 µg) of CTLA-4 blocking antibody, intraperitoneally 
(standard treatment) or low dose (50 µg) intraperitoneally. n=7 mice per group. d CTL response after low dose, 
local, treatment with CTLA-4 blocking antibody.: Nine days after start of treatment, tetramer+ CD8+ T cells were 
analyzed in spleen (mean ± SE, n=10 mice per group), data pooled of two independent experiments. Student T-test 
revealed a significant difference between treated groups and non-treated group. (p < 0.05 for both treated groups).
Local slow-release administration of CTLA-4 blocking antibody 
decreases adverse events.
In order to determine the CTLA-4 blocking antibody levels in the serum, we 
performed an anti-hamster ELISA on serum samples, taken at different intervals 
after start of treatment. As depicted in figure 2a, antibody concentrations in 
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the high dose systemically treated mice were more than 1000 fold increased 
compared to local treatment with a low dose. The CTLA-4 antibody levels in 
the latter group were only slightly elevated compared to background due to the 
combined effects of lower dose and slow local delivery. This difference in antibody 
concentrations between the systemically and locally treated groups persisted for 
at least 14 days.    
Considering the strongly decreased concentration of antibody in the serum in 
locally treated mice, we hypothesized that this treatment would induce lower 
adverse side-effects than systemic administration. In order to determine this, 
we analyzed the liver enzymes ALT and AST, known to be indicative for tissue 
damage [20], in serum samples of treated mice at several time-points after 
administration of the antibodies. As indicated in Figure 2b and c, liver enzyme 
levels were decreased in mice treated with a low dose of CTLA-4 blocking 
antibody in Montanide, compared to mice treated with the high intraperitoneal 
dose of CTLA-4 blocking antibody. 
Fig. 2 Local treatment with a low dose of CTLA-4 blocking antibody results in decreased treatment induced toxicity 
as compared to high dose, systemic treatment. Shown are CTLA-4 antibody concentrations and liver enzyme levels 
in serum in time after treatment with low dose (50 µg) local treatment or high dose (2 x 200 µg), intraperitoneal 
treatment. a Antibody concentrations in serum. b ALT levels in serum. c AST levels in serum. (mean ± SE, n=5 
mice per group) 
Since CTLA-4 blocking treatment in patients can induce serious autoimmune 
and inflammatory side-effects, we analyzed the serum-levels of anti-nuclear 
antibodies (ANA) in the mice after treatment, at several time-points between 
start of treatment and day 14, as ANAs are a strong indication of autoimmunity 
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[21]. However, we could not detect a rise in serum ANA levels in either high dose, 
intraperitoneal treatment or low dose antibody-treated mice, at any of the time-
points (data not shown).
Fig. 3 CD8+ T cells are the main effector cells involved in tumor eradication and the main target of local treatment 
with CTLA-4 blocking antibodies. Mice were depleted of CD8+ or CD4+ T cell populations, starting one day before 
tumor inoculation, for three weeks. 8 days after tumor inoculations, when palpable tumors had formed, treatment 
was started. Mice were treated with a locally provided low dose (50 µg), CTLA-4 blocking antibody, or left untreated. 
Tumor growth was measured at regular intervals. a Data represents tumor growth in each mouse, 8 mice per 
group. b Survival curve. Data is representative of two independent experiments
Local treatment depends strictly on induction of tumor specific CD8+ T 
cell responses.
To assess whether CD8+ and/or CD4+ T cells populations were important for the 
efficacy of local CTLA-4 treatment, we injected tumor bearing mice for three 
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weeks with CD8+ or CD4+ T cell depleting antibodies, starting one day before 
tumor inoculation. Seven days after tumor inoculation, when palpable tumors 
had formed, half of the mice in each group were treated with a low dose of CTLA-
4 blocking antibody that was administered locally in Montanide. Tumors in mice 
depleted of CD8+ T cells grew out at a faster rate than in control mice, regardless 
of CTLA-4 treatment. In contrast, mice depleted of CD4+ T cells, responded 
identical to CTLA-4 treatment as the control group, indicating that the presence 
of CD4+ T cell populations were not involved in tumor eradication in this model 
(Figure 3a and b). Together these data emphasize that in our tumor model CD8+ 
T cells are primarily responsible for tumor eradication and mainly targeted by 
CTLA-4 blockade. 
Discussion
In this study we show that local treatment of tumor bearing mice with CTLA-4 
blocking antibody in a slow-release formulation is very effective in activating a 
tumor-specific CD8+ T cell response, capable of tumor eradication. We further 
show that the CD8+ T cell itself is the main effector cell responsible for clearing 
the tumor, and most likely also the main target for the CTLA-4 treatment. 
Treatment-induced side effects were reduced by this local administration 
strategy compared to systemic administration, and the lower concentration of 
antibody in the serum should reduce the risk of auto-immune and inflammatory 
problems connected to clinical treatment with CTLA-4 blocking antibody. 
Local treatment with CTLA-4 blocking antibody to induce tumor eradication has 
been described before [22;23]. In these studies, the CTLA-4 blocking antibody 
treatment was given in combination with either CpG or GM-CSF secreting 
vaccines. Here, we show that the local administration is also applicable for CTLA-
4 blocking antibody as monotherapy, and that using a slow-release delivery 
system further decreases systemic levels of antibody, and thereby adverse side-
effects. 
Contrary to previous studies in mice using CTLA-4 blocking antibody [14;22;24], 
CD4+ T cells do not play an essential role in our tumor model, as evidenced by 
the fact that CTLA-4 blocking in CD4 depleted mice showed similar anti-tumor 
activity as in non-depleted control mice. This might be related to the presence of 
a tumor antigen (in our model ova) that induces a strong CD8+ T cell response. 
Also, it is conceivable that regulatory T cells play a minor role in this tumor 
model, causing the CD8+ T cell to be the major target cell for the CTLA-4 blocking 
antibody. However, we can not exclude that opposing effects might occur due 
to depletion of both effector/helper CD4+ T cells and suppressive CD4+ Tregs, 
creating a net neutral effect of CD4 T cell depletion.
CTLA-4 blocking antibody treatment did not lead to increase in autoantibody 
levels in this study, whereas clinical data shows that patients treated with 
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CTLA-4 blocking antibodies suffered from autoimmune and inflammatory side 
effects. This could be explained by the fact that patients are treated over a long 
period of time, whereas in animal models such as this study, treatment is limited 
to a few weeks. Additionally, the antibody used in mice studies, 9H10, has a 
shorter half-life than the antibodies used in patients, which can also contribute 
to the stronger adverse side-effects seen in clinical trials. 
In conclusion, this study shows that local delivery of CTLA-4 blocking antibody 
elicits tumor eradication with a relatively low dose needed, which leads to a 
decrease in treatment-induced toxicity. The main target cells of CTLA-4 
treatment in this model are tumor-specific CD8+ T cells, which are enhanced in 
number after treatment and found to be essential for tumor eradication. This 
approach lends itself without difficulty to clinical trials, because Montanide–
ISA-51 delivery is safe in human individuals [25], and because appropriate 
human CTLA-4 blocking antibodies are available [17].
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Abstract
Priming of naive CD8+ T-cells by pathogens or vaccines generally involves 
their interaction with antigen-loaded dendritic cells (DCs) in the context of an 
inflamed lymph node. Lymph node activation fosters DC and T-cell encounter, 
and subsequently provides newly primed T-cells with nurturing conditions. 
We dissected these two aspects by infusing in vitro primed CD8+ T-cells into 
naïve recipient mice harboring a single activated lymph node and comparing 
the fate of these T-cells with those infused into control recipients. Brief (20 
hr) in vitro priming empowered the T-cells to expand in vivo without further 
antigen stimulation. This primary response was not affected by the presence or 
absence of a non-specifically activated lymph node. In contrast, in vivo antigenic 
challenge after contraction of the primary response resulted in significantly 
stronger secondary T-cell responses in mice harboring activated lymph nodes, 
demonstrating that the availability of an activated lymph node supported the 
generation of T-cell memory in an antigen unrelated manner. The presence of an 
activated lymph node during the expansion and contraction phase of the primary 
response did not endow T-cells with an instructional program for increased 
survival or secondary expansion, but primarily served to conserve increased 
numbers of T-cells.
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Introduction
The initiation of T-cell responses upon primary encounter of pathogens involves 
the delivery of antigen and pathogen-associated molecular patterns (PAMPs) to 
secondary lymphoid organs draining the infected areas of the body. As a result, 
immunogenic peptide antigens are presented in MHC molecules at the surface 
of dendritic cells (DCs). Furthermore, the PAMPs trigger a sequence of events 
that orchestrate effective interaction between antigen-loaded DCs and naïve 
T-cells, including the expression of costimulatory molecules at the DC surface 
and the production of pro-inflammatory cytokines and chemokines that recruit 
and arouse a variety of immune cells. (1)  The latter process causes lymph 
nodes to develop a state of inflammation and swelling, also referred to as lymph 
node congestion or activation(2). Chemokines like CCL9 and CCL21, cytokines 
including TNF-alpha and IFN-α/β, and the chemo-attractant receptor S1P all 
play an important role in enhancing the cellularity of the lymph node during 
an immune response, thereby creating an inflammatory micro-environment 
supportive of T-cell priming.(3-8) The significance of PAMPs such as Toll-like 
receptor ligands in the induction of T-cell immunity has been demonstrated in 
numerous experimental models, showing that delivery of antigen without PAMPs 
as immune-adjuvants results in T-cell tolerance. Even though the importance of 
PAMPs for inducing costimulatory signals through DC activation as well as for 
triggering lymph node activation is broadly recognized, and the nature of the DC 
costimulatory signals has been studied in great detail (9,10), much less is known 
about the impact of lymph node activation on the effector and memory phases of 
the T-cell response. In the present study, we have focused on the latter aspect by 
separating DC-T cell engagement and lymph node activation in place and time. 
Our experimental data reveal that the availability of an inflamed lymph node 
during the primary response increases the magnitude of the secondary response 
through the conservation of larger numbers of T-cells. 
Material and Methods:
Mice:
C57BL/6 jico (B6) mice were obtained from Jackson laboratories. OT-I TCR Tg 
RAG-1-/- mice were from W. R. Heath (The Walter and Eliza Hall Institute of 
Medical Research, Victoria, Australia) and were bred in the animal facility of 
LUMC.v The experiments were approved by the animal experimental committee 
of Leiden University Medical Center.
Cell culture:
All in vitro cell culture and assays were performed in IMDM (Invitrogen Life 
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Technologies, Rockville, MD) supplemented with 8% v/v FBS (Greiner), 50 µM 
2-ME, 2 mM glutamine, 100 IU/ml penicillin (complete medium). D1 cell line, 
a long-term growth factor-dependent immature splenic DC line derived from 
B6 mice, was kindly provided by P. Ricciardi-Castagnoli (University of Milano-
Bicocca, Milan, Italy) and cultured as described (11). BM-derived DC were isolated 
from C57BL/6 jico femurs, cultured for 10 days in the same manner as D1 cells, 
before activation. The engineered APC cell line MEC.B7.SigOVA (SAMBOK) 
was generated as described (12), briefly, the mouse embryonic fibroblast cell line 
MEC-1 was transfected with CD80 and the minigene SigOVA, which encodes 
the OVA257-264 (SIINFEKL) peptide directed to the ER, leading to efficient loading 
of the peptide onto MHC Class I molecules Kb. For in vitro priming, engineered 
APC were cultured at 70000 cells/well in 24 well plates overnight. The next day, 
nonadherent cells and cell debris were removed by washing the wells twice. 
OT-I cells were then added to the wells (0.5×106/well) in 2 ml of medium and 
plates were centrifuged for 1 min at 1000 rpm to initiate cell contacts. After 
20h of co-culture the nonadherent OT-I cells were gently harvested, washed and 
adoptively transferred into recipient mice.
Lymph node activation: 
D1 cells were cultured in D1 medium, maturation was induced by adding 6 µg/
ml LPS (E-coli derived, serotype 026, B6, Sigma) 24 hours before injection. Cells 
were harvested with EDTA, washed three times with PBS, and injected, 2×106 in 
30 µl PBS into the right hind leg footpad of mice.  
In vivo challenge:
50 µg of synthetic short OVA peptide (SIINFEKL) was injected with 15 µg CpG 
1826 (synthesized in the Leiden Institute of Chemistry) in 30 µl PBS into the 
right hind leg footpad of mice. 
Flowcytometry:
All antibodies were purchased at BD and eBioscience. Intracellular cytokine 
staining was performed with the Cytofix/Cytoperm kit (Becton Dickinson) 
according to manufacturer’s instructions. 
In vitro proliferation assay;
Lymph nodes from mice were isolated from recipient mice and single cells 
suspensions were generated by mincing through cell strainers. Subsequently, 
cells were stained with CD8 and CD45.1 mAbs, and OT-I cells were purified by 
flowcytometric sorting. Equal amounts of cells were co-cultured with 100.000 
irradiated spleen cells, and 1 µg/ml SIINFEKL, or medium control. 36 hours 
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later, cells were pulsed with 1 µC 3H per well, and analyzed 24 hours later.
Virus-infection:
Mice were infected with 5× 104 pfu influenza A/WSN/33 (WSN)-OVAI (13) through 
intra-tracheal inoculation. After 5 days mice were sacrificed, and lungs were 
isolated in TRizol (Gibco) and homogenized. RNA was extracted and purified 
using the Qiagen RNeasy kit, cDNA was synthesized using 7.5 microgram RNA 
of each sample, and 12.5% cDNA was used in the RT-PCR reaction, in triplicate, 
and correlated to actin expression (primer/probe Applied Biosystems). cDNA 
synthesis and RT-PCR were performed using primer-sequences as described 
before (14)
Results
Activated lymph nodes provide increased storage for antigen-
experienced T-cells
Lymph node activation is an intrinsic aspect of T-cell activation by infectious 
pathogens and vaccines. We separated the T-cell priming event from lymph node 
activation in space and time by exploiting an experimental model consisting of 
TCR-transgenic OT-I CD8+ T-cells and engineered APCs expressing high levels 
of the cognate ovalbumin (OVA)-derived peptide epitope and the costimulatory 
ligand CD80. Prior work had demonstrated that a 20-hr in vitro encounter 
with these APCs empowered naïve OT-I cells to vigorously proliferate in vivo 
upon transfer to naïve syngeneic recipient (15) Furthermore, these T-cells were 
shown to develop into long lived memory cells, capable of clonal expansion and 
protective effector function in response to secondary antigen encounter (16). 
Importantly, progression of the 20-hr primed OT-I T-cells through primary 
expansion, contraction and memory phases required neither in vivo exposure 
to antigen, nor the context of an inflamed, congested lymph node. This model 
therefore offered a unique opportunity to compare the in vivo behavior of primed 
CD8+ T-cells in the absence versus presence of a non-specifically activated lymph 
node. Activation of a single, popliteal lymph node in recipient mice was induced 
by footpad injection of activated syngeneic DCs (D1 cells or isolated BM-DCs) 
that were not loaded with antigen. Work by others has shown that this results 
in inflammation of the targeted lymph node within 1 day (8). The use of DCs not 
loaded with OVA antigen enabled us to separate the impact of antigen exposure 
and lymph node congestion in time and space. Comparison of the behavior of 
20-hr ex vivo primed OT-I cells upon injection into DC-injected versus control 
mice revealed very few differences in the kinetics and magnitude of the primary 
response. 
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Figure 1: Kinetics and magnitude of the primary in vivo response by 20 h in vitro primed OT-I cells.
CFSE-labeled naïve CD45.1 OT-I cells were cultured during 20 hrs with engineered APCs expressing OVA antigen 
and CD80, after which T-cells were separated from the APCs and injected into antigen-naïve B6 mice (1 ×106 per 
mice) as described previously (15). Recipient CD45.2 mice either did not receive prior treatment, or were injected 
into the footpad of the right hind leg with 2 × 106 in vitro, LPS-activated DCs (D1 cells), not loaded with antigen, 
24 hrs prior to T-cell infusion . Blood samples were isolated at days 3 and 10 after start of T-cell activation. At 
day 22, mice were sacrificed and spleen and lymph nodes isolated. Panels A/B and C/D were from subsequent 
experiments with similar outcome. OT-I cells were gated by CD8 and CD45.1 A. Representative examples of groups 
of 4 mice (A, B ) of proliferative response (CFSE) and relative OT-I cell counts in blood of DC-injected and control 
mice. B. Accumulation of memory OT-I cells during the post contraction phase in popliteal lymph nodes and spleen 
of DC-injected and control mice. Right-hand lymph nodes of DC-injected mice were inflamed. Contra-lateral, left-
hand lymph nodes from DC-injected mice served as internal control. N.A. = not applicable.  Three independent 
experiments were performed (A and B) C. Percentage of OT-I cells, in relation to total cell counts, in congested, 
right-hand lymph nodes of DC injected mice and the same lymph nodes from control mice in post contraction 
phase. Comparison revealed no difference in both effector and post contraction phase. D. Absolute total cell count 
and OT-I T cell count in congested, right-hand lymph nodes of DC injected mice and the same lymph nodes from 
control mice. Mann-Whitney test revealed significant differences in total and OT-I numbers in effector phase as 
well as in memory phase, 5 mice per group, two experiments pooled. Four independent experiments performed in 
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In both cases, the percentage of circulating OT-I cells peaked at day 3 after 
transfer, followed by a rapid contraction due to the absence of cognate antigen 
(Fig 1A). Three weeks after transfer, at a time when OT-I numbers in the 
blood were below detection, memory T-cells could still be detected in the spleen 
and lymph nodes (Fig 1B). As observed in the primary phase, percentages of 
memory OT-I cells differed neither between DC-injected and control mice (Fig 
1C). However, the absolute total cell count was increased in the inflamed lymph 
nodes compared to contra-lateral lymph nodes in DC–injected mice and lymph 
nodes in control mice. Consequently, also the absolute numbers of OT-I cells 
were amplified in these lymph nodes, both at the peak of the effector phase and 
during the post-contraction phase of the primary response (Fig 1D). For inflamed 
lymph nodes, the total cell count was even larger in the post-contraction phase 
(day 22) than during the effector phase, in line with the notion that the size 
of the inflamed lymph nodes gradually increases and remains fully enlarged 
over at least 3 weeks. (data not shown). Taken together, our data suggest that 
the primary role of an inflamed, enlarged lymph node is to provide an expandable 
storage reservoir for memory T-cells.
Memory T-cell storage is important for the magnitude of the secondary 
T-cell response
Our initial observations prompted us to test how accumulation of greater 
numbers of memory T-cells in a single inflamed lymph node would impact on the 
systemic CD8+ T-cell response upon secondary antigen encounter. We delivered a 
secondary antigenic challenge to the in vitro primed OT-I cells through injection 
of ovalbumin peptide and CpG ODN into the footpad of the right hind leg, the 
same footpad into which mice with inflamed lymph nodes received their initial 
DC injection. In line with the greater number of memory T-cells available in 
these LNs in DC-injected mice, secondary responses in these mice were stronger 
than in control mice (Fig 2A, B). Moreover, the secondary responses in DC-
injected mice were stronger than as compared to the primary responses recorded 
in these same mice, reminiscent of a textbook example of the relative magnitude 
of primary and secondary T-cell responses. Differences between DC-injected and 
control mice were most prominent in the blood and lung (Fig 2B), illustrating that 
secondary challenge of the DC-injected mice resulted in increased frequencies of 
effector T-cells capable of leaving the lymphoid organs and migrating to potential 
target tissues. Differences in OT-I T-cell frequencies were the least prominent in 
the draining lymph nodes, in line with this migratory behavior of effector T-cells 
and the increased overall cellularity of these lymph nodes (Fig 1D). Similar 
results were obtained in mice with an activated lymph node induced by injecting 
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bone-marrow derived DC. (data not shown).
Interestingly, the secondary responses in control mice did not exceed the 
magnitude of the primary responses (Fig 2A). Our experiments therefore reveal 
that the availability of an inflamed lymph node during the primary response 
is important for the generation of an enhanced secondary T-cell response. 
Because secondary antigen challenge in our experiments involved co-delivery of 
CpG ODN, causing efficient activation of the draining lymph nodes in both DC-
injected and control mice, we deem it unlikely that the already inflamed status 
of these lymph nodes in DC-injected mice is a key determinant in facilitating the 
secondary response of the T-cells. The most likely explanation for the stronger 
secondary response in DC-injected mice is therefore the greater number of CD8+ 
memory T-cells conserved after contraction of the primary response elicited from 
the inflamed lymph nodes.
 
Figure 2: Presence of inflamed LN during primary response increases magnitude secondary T-cell response
Primary responses of ex vivo primed OT-I cells were followed over time in the blood in mice that had received a footpad-injection 
of LPS-activated DCs, not loaded with antigen, and in control mice. At day 28, after contraction of the primary response, mice were 
challenged with 50 µg synthetic OVA peptide (SIINFEKL) comprising the OT-I T-cell epitope in combination with 15 µg CpG. This 
antigen challenge was delivered into the footpad of the right hind leg, at the same site of DC injection. A. Kinetics of OT-I in blood 
in control and DC-injected mice, mean of three mice per group with standard error of the mean. Arrow indicates time of antigen 
challenge. Representative of three experiments B. Mean values for percentages of OT-I cells in different compartments around peak 
of secondary response (day 8 after secondary challenge) for 14 mice/group. Mann-Whitney test revealed statistically significant 
differences between groups in blood and lung (p=0.02 and p=0.03 respectively), but not in spleens and draining LNs (p=0.13 and 
p=0.33 respectively). Two independent experiments performed.
To further analyze the conditions in inflamed lymph nodes in DC-injected mice, 
we performed footpad injection of CFSE-labeled DCs. As shown in Fig 3A, this 
results in a rapid increase, within 1 day, of the absolute numbers of various 
types of cells, including T-cells, B-cells and CD11c+ DCs. The increase in 
CD11c+ cell numbers cannot be attributed by the injected DCs, because CFSE-
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(data not shown). The host-derived cells recruited to the inflamed lymph node 
displayed an activated state, as illustrated by the increased frequencies of IL-12 
producing CD11c+ cells and TNF-alpha producing CD3+ cells (Fig 3B). There 
findings strengthened the notion, based on experiments shown in Fig.1C/D, that 
the injection of activated DCs triggers an overall accumulation of APCs and 
lymphocytes rather than a selective accumulation and/or activation of antigen-
specific OT-I T-cells. Accordingly, we did not find significant differences in the 
activation status, as determined by IFN-gamma production, of ex vivo primed 
OT-1 cells between inflamed and resting lymph nodes of DC-injected and control 
mice respectively, neither in the effector phase, nor in the post contraction phase 
of the primary response (Fig 3C). Evaluation of additional markers that were 
found to be associated with T-cell activation and memory cell formation, in 
particular CD62L, CD127, CD122, CCR7 and TRAIL (17-19), also failed to reveal 
a qualitative difference between the OT-I T-cells in resting versus inflamed 
lymph nodes (supplementary figure 1 and data not shown).
Figure 3: Conditions in the inflamed LN
Cellularity and cytokine production in inflamed and control LN was analyzed 24h after footpad-injection of LPS-activated DC’s. 
Single cell suspensions of LN were stained for CD19, CD3 and CD11c A:. Absolute numbers of cells in inflamed and control LN. 
B: Percentage cytokine producing cells in inflamed and control LN 24h after footpad-injection of DC. Cytokine production was 
analyzed by intracellular cytokine staining following PMA/ionomycin activation. In each experiment 4 mice per group were used. 
Mann-Whitney test revealed statistically significant differences in IL-12p40 and TNF-alpha production between groups (p=0.03 
and p=0.02 respectively).  Two independent experiments performed. C: IFN-gamma production by OT-I CD8+ T-cells at day 3 
and 26 after start of T-cell activation. Single cell suspensions of LN were analyzed by intracellular cytokine staining following 3h 
stimulation with SIINFEKL peptide in vitro. Mann-Whitney test revealed no significant difference between groups in effector and 
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The possibility of a qualitative rather than a mere quantitative difference between 
OT-I cells in DC-injected and control recipient mice, was further investigated 
by harvesting OT-I memory T-cells from mice with inflamed lymph nodes in 
the early post-contraction phase (12 days after infusion), and transferring these 
– in identical numbers - to either DC-injected or control recipients (Fig 4A). 
T-cells were allowed to rest for another 15 days in new recipients, after which 
they encountered a secondary antigenic challenge through footpad injection of 
OVA-peptide/CpG. Analysis of the secondary in vivo OT-I responses showed 
that the availability of an inflamed lymph node in the recipient mice was of key 
importance for a strong, systemic memory T-cell response (Fig 4B). Thus, post-
contraction OT-I T-cells harvested from inflamed lymph nodes only persisted in 
greater quantities when transferred into DC-injected recipients, and therefore 
did not exhibit an intrinsic capacity for survival independent of the availability 
of an inflamed lymph node. In reciprocal experiments, we found that post-
contraction OT-I cells harvested from control mice led to stronger secondary 
responses in magnitude when infused into DC-injected mice than when infused 
into control mice (Fig 4C) supporting the notion that inflamed LN supports 
memory T cell maintenance and CD8+ memory T-cells ‘educated’ in DC-injected 
and control mice did not differ intrinsically. In order to determine if the OT-I T 
cells from DC-injected mice reacted differently to antigenic stimuli, OT-I T-cells 
cells were recovered, at day 7 and day 24 after adoptive transfer, from lymph 
nodes of DC-injected and control mice, and co-cultured in vitro with feeders and 
specific peptides. Proliferation to the specific peptide was analyzed by tritium 
incorporation. (Fig 4D) Although a trend towards more proliferation at day 7 
in the DC-injected group was observed, this difference was not significant. At 
day 24, no difference between OT-I cells from DC-injected versus control mice 
to the antigenic challenge was observed. . This supports our hypothesis that the 
amplified response in vivo in DC-injected mice is due to quantitative difference 
caused by the larger absolute numbers of antigen-experienced T-cells in the 
inflamed lymph node. 
Importance of memory T-cell conservation by inflamed lymph nodes in 
anti-viral immunity
So far, our experiments demonstrated that secondary challenge at the site of 
prior lymph node activation can result in a superior memory T-cell response. 
In additional experiments, we delivered the secondary antigenic challenge, 
consisting of ovalbumin peptide and CpG ODN, in the ipsilateral footpad. 
Antigen delivery at this site resulted in a secondary T-cell response comparable 
to that elicited by antigen delivery in the foot pad near the inflamed lymph 
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node, showing that the locally conserved memory T-cells can be recruited into 
secondary responses triggered by antigenic delivery at distal sites (data not 
shown). To further assess the physiological significance of memory CD8+ T-cell 
conservation in inflamed, local lymph nodes, we infected OT-I recipient, DC-
injected and control mice intra-tracheally with recombinant influenza virus 
encoding the ovalbumin antigen (13)
Figure 4: T-cells educated in inflamed 
LN are not intrinsically changed
T-cells recovered from inflamed or 
control LN were counted and adoptively 
transferred in identical numbers (103 
OT-I cells/recipient) into new recipients 
with or without inflamed LN. Response 
to a boost vaccination was analyzed in 
blood, spleen, lung and draining LN. 
A: Schematic cartoon of experimental 
design. B: Mean values for percentages 
of OT-I cells educated in mice with 
inflamed LN in different compartments 
around peak of secondary response (day 
8 after secondary challenge) 4 mice/
group. Mann-Whitney test revealed 
significant differences for blood, spleen 
and lung (p=0.03 for all compartments) 
but not draining LN (p=0.34) between 
groups. C: Mean values for percentages 
of OT-I cells educated in control mice 
in different compartments around peak 
of secondary response (day 8 after 
secondary challenge) 4 mice/group. 
Mann-Whitney test revealed significant 
differences for blood, spleen, lung and 
draining LN (p=0.03, p+0.01, p=0.01 
and p=0.02 respectively) between 
groups. Two independent experiments 
performed (A and B)
T-cells recovered from inflamed or 
control LN at day 7 and day 24 were 
isolated by flow-cytometric sorting and 
co-cultured with irradiated spleen cells 
and SIINFEKL peptide in equal amounts 
(1250 cells/well for day 7, 500 cells/well 
for day 24). After  36 hours, cells were 
pulsed with tritium and incorporation was measured 24 hours later. Stimulation index was calculated as tritium count with peptide 
divided by tritium count of medium control. C: Stimulation index of OT-I cells recovered on day7 and day 24 respectively. Groups of 
5 (day 7) and 10 (day 24) mice. Mann-Whitney test revealed no significant differences between groups. Mann-Whitney test revealed 
no significant differences on day 7 and day 24 (p=0.25 and 1.0 respectively).
As shown in Fig 5, DC-injected OT-I recipients have a significantly lower amount 
of virus particles in their lungs. This can be explained by the fact that DC-injected 
recipients develop a memory T-cell response superior to that of control OT-I 
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Figure 5: Presence of inflamed LN during 
primary response enhances anti-viral 
immunity
A secondary response to an influenza virus 
containing the SIINFEKL epitope is more 
vigorous in mice with an inflamed LN, 
induced by injecting LPS-activated DC not 
loaded with antigen into the footpad of mice, 
during the primary response. Mice with an 
inflamed LN or control mice were adoptively 
transferred with in vitro activated OT-I 
T-cells. After 35 days mice were infected 
with 5×104 PFU influenza virus through 
intra-tracheal injection. 5 days later viral load 
in the lungs was determined by quantitative 
PCR. Mann-Whitney test revealed significant 
reduction of virus RNA in DC-injected mice 
compared with control mice. (P=0.05) 8 mice 
per group. 
Discussion
By separating DC-T-cell engagement and lymph node activation in space and 
time, we demonstrated that the presence or absence of an activated lymph node 
has no impact on the magnitude and kinetics of the primary response, at least 
in the absence of cognate antigen, but clearly influences the magnitude of the 
memory T-cell response upon secondary antigen encounter. Furthermore, our 
data show that presence or absence of an activated lymph node does not imprint 
intrinsic differences into the T-cells that would result in alternate survival or 
memory programs. Instead, the activated lymph nodes appear to primarily offer 
increased storage space for antigen-experienced T-cells during the contraction 
and memory phases of the primary response. This offers opportunities for using 
lymph node inflammation in conditioning patients for adoptive T-cell transfer 
strategies. Aswell as the current method of lympho depletion, lymph node 
inflammation
can create a nurturing environment for newly injected T-cells. Our findings 
differ from those emerging from studies that have looked at the impact of signals 
at the DC-T-cell interface on the development of T-cell memory. For instance, the 
presence of costimulatory signals involving the 4-1BB and OX40 pathways during 
T-cell priming imprints a survival program that promotes development of T-cell 
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memory and enhanced secondary T-cell responses(20,21) (22). Furthermore, the 
presence of CD4+ T-cells during CD8+ T-cell priming was shown to render CD8+ 
T-cells insensitive to TRAIL-mediated death during the secondary response, 
thereby endowing them with the capacity to mount an enhanced memory T-cell 
response (17,23). These prior studies and our present work imply that T-cell 
programming during DC-T-cell engagement and the availability of enlarged 
lymph nodes for T-cell storage are expected to synergize in the generation of 
potent T-cell memory. 
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Abstract
Slow-release delivery has great potential for specifically targeting immune-
modulating agents into the tumor-draining area. In prior work we showed 
that local treatment of slowly delivered anti-CD40 antibody induced robust 
anti-tumor CD8+ T cell responses without systemic toxicity. We now report on 
the comparison of two slow-release delivery systems for their use in antibody-
based immunotherapy of cancer. Anti-CD40 antibody delivered locally in either 
Montanide ISA 51 or dextran-based microparticles activated tumor-specific T cell 
activation. Both slow-release methods decreased systemic side-effects significantly 
compared to systemic administration of anti-CD40 agonistic antibody. However, 
dextran-based microparticles caused serious local inflammation associated with 
enhanced outgrowth of tumors instead of the tumor clearance observed with 
delivery in Montanide. We therefore conclude that Montanide ISA 51 is to be 
preferred as a slow-release agent for immunotherapy of cancer
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Introduction:
CD8+ T cells have the potential to eradicate tumors since many tumors express 
aberrant antigens [1, 2]. The induction of anti-tumor T-cell priming, however, is 
often ineffective [3]. The inactive state of dendritic cells (DCs) cross-presenting 
tumor antigen in the draining lymph node (LN) is one of the main reasons. 
Inadequate CD4+ T cell help and lack of danger signals are responsible for the 
inactive state of the DC[4]. 
Strategies aimed at activating anti-tumor CD8+ T cells directly or indirectly 
via tumor antigen presenting DCs have now been shown to be therapeutically 
useful in the treatment of cancer [5-7].  Monoclonal antibodies that modulate the 
immune system, such as 4-1BB, OX40 and CD40 agonists and CTLA-4 and PD-1 
blocking antibodies, are available, and many are currently being investigated 
in pre-clinical and clinical studies [5-7]. Systemically activating the immune 
system, however, is perilous since this can cause adverse side-effects and risk 
initiating auto-immunity [8-10].
Previously we have shown that local administration of an agonist antibody 
against the TNF receptor family member CD40 can activate the local tumor 
antigen presenting DC, thereby indirectly activating the anti-tumor CD8+ T cell 
response. By using a slow-release system, Montanide-ISA51, this treatment was 
local, with significantly decreased adverse side-effects compared to the standard 
systemic treatment. This local, non-toxic, treatment, however, was capable 
of activating a systemic CD8+ T cell response, associated with eradication of 
both local and distant tumors [10].  We hypothesize that this strategy could be 
successful for many monoclonal antibodies aimed at activating the anti-tumor 
CD8+ T cells, tumor-antigen presenting DCs or blocking tumor induced immune 
suppression. 
We now report on the exploration of two different slow-release systems, in order 
to specifically target the antibodies to the tumor-draining area at a release rate 
suitable for an antibody. In particular we compared the potential of dextran-
based microparticles as a slow-release system for targeting immune-modulating 
antibodies in the tumor-draining area, with delivery in Montanide ISA 51. 
Dextran-based microparticles are reportedly a well-regulated slow-release agent, 
which can be tailored to display the exact pharmaco-dynamic kinetics required 
for the encapsulated substance, with possibilities to mix particles encapsulating 
different substances with different release rates [11-13]. Dextran is a water-
soluble polysaccharide that has good biocompatability, relative stability and a 
large number of hydroxyl groups, making it widely used as a polymeric building 
block for the design of hydrogels. Dextran-based injectable microparticles loaded 
with proteins can be prepared in an aqueous two-phase system avoiding the use 
of organic solvents. We have previously shown that the release of proteins from 
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these particles depends on the equilibrium water content and their degradation 
rate [14]. 
To investigate the use of dextran-based microparticles for delivering immune-
modulating antibodies in the tumor-draining area, we analyzed the release 
kinetics and biological activity of antibodies encapsulated in different dextran-
based microparticles. Agonistic CD40 antibody was used as our model immune-
modulating antibody. We show that dextran-based microparticles can deliver 
agonistic CD40 antibodies with slow-release kinetics that can lower adverse 
side-effects by decreasing the serum levels of the antibodies. Our studies show 
that both dextran and Montanide release systems induce robust CD8+ T cell 
responses. However, dextran-based particles caused serious local inflammation, 
creating subcutaneous ulcerating lumps at the site of injection associated with 
enhanced outgrowth of tumors. We therefore conclude that Montanide ISA51 
should be preferred as slow-release delivery system for anti-CD40 agonistic 
antibody treatment for cancer immunotherapy.  
Material and methods
Mice
C57BL/6 mice were purchased from The Jackson Laboratory. C57BL/6 Kh (B6, 
H- 2b) were bred at the LUMC animal facility. The experiments were approved 
by the Animal Experimental Committee of the University of Leiden.
Tumor experiments
Mouse embryonic cells transformed by the early region 1A of human adenovirus 
type 5 (Ad5E1A) plus EJ-ras were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM): (BioWhittaker, Verviers, Belgium) supplemented with 4% 
FCS, 50 μM 2- mercaptoethanol and 100 IU/ml penicillin/streptavidin. The E1A 
expressing tumor cells (7.5 x 106) were injected s.c. into 7-13 week-old male mice 
in 200 μl of PBS. Treatment was started 8-14 days after tumor inoculation, when 
palpable tumors were present.  Tumor size was measured twice weekly in three 
dimensions and mice were killed when tumor size exceeded 1 cm3 .
Flow cytometry
Single-cell suspension of blood and spleens, after erythrocyte lysis, and lymph 
nodes were stained with anti-CD8a (clone 53-6.7), CD90.1 (clone OX-7),) CD3ε 
(clone 145-2C11), CD19 (clone 1D3), and CD3e (clone 145-2C11), anti-CD11c 
(clone HL3) and CD86 (clone GL1) all from BD Bioscience and E1A234-243-loaded 
H-2Db tetramers
Agonistic CD40 antibody treatment
The FGK-45 hybridoma cells producing an agonistic anti-CD40 Ab were 
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provided by A. Rolink (Basel Institute for Immunology, Basel, Switzerland) [17]. 
Hybridomas were cultured in Protein Free Hybridoma Medium (Gibco), and mAbs 
were purified using a Protein G column. Mice treated with high dose, systemic 
treatment were injected with 100 micrograms of antibody in PBS intravenously, 
on three consecutive days. Montanide/antibody emulsions were made by mixing 
different dosages of antibody in PBS 1:1 with Montanide (Montanide ISA-51, 
Seppic), and vortexing for 30 minutes.
Dextran-based microparticles encapsulating anti-CD40 antibody
Dextran-based microparticles were prepared as described elsewhere [18]. In 
brief; for dextran microspheres with a protein load of 1% w/w (weight antibody/
weight dex-hema) dextran-HEMA (hydroxyethyl methacrylate derivatized 
dextran) with a DS of 9.7 (degree of HEMA substitution; the number of HEMA 
groups per 100 glucose units, synthesis described in van Dijk-Wolthuis et al. 
[19] was dissolved in an aqueous solution containing the antibody. All solutions 
had been deoxygenized by flushing with nitrogen for 5 minutes. The ratio of 
dex-HEMA solution to the PEG aqueous solution was varied, in order to obtain 
particles with different release kinetics. The PEG/dex-Hema/water system was 
vortexed for 1 minute and subsequently the dextran-bound HEMA groups were 
polymerized using TEMED and KPS to yield crosslinked dextran microparticles. 
After 1 hour of incubation, the microparticles were washed three times with 
PBS, to remove traces of PEG, and freeze-dried. Average particle size diameters 
and size distributions of the microspheres were measured with an AccuSizer 780 
with water as diluent. 
In vitro release assay
Microparticles were weighed, dispersed in PBS and incubated at 37˚C under 
rotation. Samples were taken at regular intervals, and protein content was 
determined by Bradford analysis[20]. Percentage of protein release was 
calculated as amount of protein analyzed divided by total protein encapsulated. 
Total protein encapsulated was determined by Bradford analysis of the burst 
release of microspheres at pH 11. 
Serum analyses
Serum samples were taken from mice at several time points after treatment. 
ALAT and ASAT analyses were performed by the department of Clinical 
Chemistry of the LUMC according to standard protocols [21]. Anti-CD40 
antibody concentrations were analyzed by ELISA with anti-rat antibodies (BD 
bioscience).
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In vivo analysis of strain 42 proliferation
Spleen and lymph nodes were isolated from Strain 42 mice, and CD8+ T cells were 
enriched using the BD Imag CD8+ enrichment kit, according to manufacturer’s 
instructions. 1 million CD8+ T cells were injected intravenously into recipient 
mice, bearing palpable AR6 tumors. 4 days later, mice were treated with anti-
CD40 in Montanide, encapsulated in different dextran-particles subcutaneously, 
close to the tumor, or left untreated. Blood samples were taken at regular 
intervals, and the percentage of Strain 42 cells of the CD8+ population was 
determined by flowcytometry, using the CD90.1 congenic marker, and serum 
levels of anti-CD40 antibody was determined by ELISA. 
Results
In vitro and in vivo release from dextran-based microparticles
In order to determine whether dextran-based microparticles could be a suitable 
slow-release system for the use in tumor immunotherapy, we prepared dextran-
based microparticles containing CD40 agonistic antibody, with different water 
content. By adjusting the water content, the antibody release characteristics of 
the particles can be modulated. The size of the particles ranged from 5 to 30 
µm. The protein encapsulation was determined to be 95%. The in vitro release 
kinetics is depicted in figure 1A. Approximately 80% of the antibody was released 
from the microparticles over 30 day. Increase in water in the particle correlated 
with increase in rate of release. The mix of equal amounts of particles with 70%, 
60% and 50% of water showed a constant rate of release, whereas the 50% water 
particles showed an initial delay of several days. We next established the in vivo 
release of antibody from particles, and correlated this to the biological activity 
of the antibody in the well-defined adenovirus induced AR6 tumor model[15]. 
Tumor-bearing mice were injected with enriched CD8+ T cells from strain 42 
mice, a TCR transgenic mouse strain whose CD8+ T cells recognize the E1A 
epitope of the AR6 tumor. Subsequently these mice were injected sc with various 
dextran-particles containing anti-CD40 antibody. We used a dose of 30 µg of 
antibody, as was previously described to be very effective in Montanide [16]. 
The level of serum antibody was determined at various intervals, and correlated 
to the proliferation of the strain 42 CD8+ T cells. Figure 1B shows that the in 
vivo release of the antibody did not correlate with release kinetics in vitro, as 
neither the 70% nor 50% water containing particles nor the mix of 70, 60 and 
50% particles displayed any delay in release in vivo. Additionally, the release of 
antibody from the dextran-particles was detectable in vivo for a maximum of 12 
days, whereas the in vitro release continues for more than 20 days. However, the 
level of antibody in the serum was lowest in the 50% water particles in line with 
the expected slowest release rate. This obviously shows that other factors play a 
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role in degrading anti-CD40 particles in vivo.
Importantly, each of the delivery conditions was biologically active, since in 
every group a proliferative response of the Strain 42 T cells was activated as 
depicted in figure 1C. Each of the dextran-treated groups activated a stronger 
response than the Montanide treated mice, and the 50% water- containing 
dextran-particle group showed the highest proliferative capacity. We therefore 
concluded that the particles with 50% water were the most suitable formulation, 
since this had advanced biological activity locally, but showed the least amount 
of antibody systemically. 
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Figure 1: In vitro and in vivo release of dextran-based encapsulated antibody. Dextran-based microparticles were 
dispersed in PBS, and incubated at 37 ˚C. Samples were taken at regular intervals, and antibody levels were 
determined by Bradford analysis (A). In vivo release of antibody, correlated with biological activity of released 
antibody. Tumor bearing mice were injected with 1x 106 enriched strain42 CD8+ T cells, and treated with anti-
CD40 antibody in dextran-based microparticles or anti-CD40 in Montanide. Bloodsamples were taken at regular 
intervals, and antibody levels were analyzed in serum by ELISA, and strain42 CD8+ T cell proliferation by 
flowcytometry (B) (mean ± SE, n= 4 mice per group).  Data are representative of two independent experiments.
CD40-induced toxicity
As we previously published, systemic treatment with CD40 antibody causes 
strong adverse side-effects, as analyzed by serum levels of liver enzymes and 
tissue damage assessed histologically [16]. In order to determine the adverse 
side-effects caused by treatment with 50% water containing microparticles, 
compared to high dose systemic treatment or low dose Montanide treatment. We 
assessed serum levels of liver enzymes ALAT and ASAT, as they are indicative 
for liver and tissue damage respectively. Compared to the high dose systemic 
treatment of anti-CD40 antibody, both low dose treatments showed clear 
decrease in ALAT and ASAT levels, as was expected from our previous study 
with Montanide (Fig 2A). When comparing only Montanide with the dextran 
formulations, however, the ALAT levels were even lower in the dextran-group, 
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as predicted from serum levels of antibody, whereas for ASAT levels there is 
no difference between dextran-treated and Montanide-treated mice (Fig 2B). 
We therefore conclude that the low level systemically released antibody in 50% 
water-containing dextran-particles induces no detectable systemic toxicity.
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Figure 2: Systemic toxicity caused by antibody treatment. Mice were treated with different dosages and 
administration methods of anti-CD40 agonist Ab. Serum samples were taken at regular intervals. (A); ALAT and 
ASAT levels in serum, mice treated with high dose anti-CD40 antibody (2 x 100 µg) intravenously compared to mice 
treated with low dose (30 µg), either in Montanide, or encapsulated in dextran-based microparticles. (B); ALAT and 
ASAT levels in serum, low dose (30 µg) anti-CD40 antibody in Montanide treated mice compared to low dose (30 
µg) dextran-based microparticles treated mice. (mean ± SE, n=5 mice per group). 
Activation of the endogenous anti-tumor response
To examine whether a low dose (30 ug) of anti-CD40 antibody delivered in 50% 
water-containing dextran-based microparticles could activate an endogenous 
anti-tumor CD8+ T cell response, we treated tumor-bearing animals with different 
formulations of slow-release vehicles with agonistic anti-CD40 antibody.Ten 
days later we sacrificed the mice, and analyzed the presence of tumor-specific 
CD8+ T cells with tetramer staining and specific interferon-gamma expression in 
spleen. As shown in figure 3A and B, both high dose treatment and the low dose 
Montanide treatment activate a strong tumor-specific CD8+ T cell response, both 
detectable with tetramer and cytokine expression. In contrast, the dextran-based 
treatment activated a much lower tumor-specific CD8+ T cell response, similar 
to levels of untreated mice in the tetramer-staining, but slightly elevated in 
interferon-gamma expression as compared to untreated controls. Unexpectedly, 
dextran-based treatment seemed less effective in activating the endogenous 
response than in activating the TCR transgenic CD8+ T cells. The anti-CD40 was 
capable of activating the dendritic cells in the injection area, as the CD86 (B7.2) 
expression on CD11c+ cells in the LN draining the injection site was increased 
(fig 3C). The B7.2 expression on DC was highest in the Montanide treated mice, 
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and mice treated with dextran particle-packaged antibody displayed an elevation 
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Figure 3: Endogenous immune response 
after dextran-based treatment. Tumor 
bearing mice were treated with high dose 
(3*100 µg) intravenously compared to 
mice treated with low dose (30 µg) anti-
CD40 antibody, either in Montanide, 
or encapsulated in dextran-based 
microparticles. Spleen were analyzed for 
tetramer+ CD8+ T cells and IFN-gamma 
expression 9 days after start of treatment 
(A, B) (mean ± SE, n=4 mice per group) 
data representative of two independent 
experiments. Activation of dendritic cells 
in lymph nodes after treatment with 
low dose (30 µg) anti-CD40 antibody, 
either in Montanide, or encapsulated in 
dextran-based microparticles. B7.2 (CD86) 
expression on CD11c high cells in draining 
versus non-draining lymph nodes of tumor-
bearing mice (C). Students T-test revealed 
significant difference in B7.2 expression 
on DC between draining and non-draining 
lymph nodes of Montanide treated mice 
(P=0.03) (mean ± SE, n=4 mice per group), 
data representative of two independent 
experiments. 
Eradication of tumors after dextran-particle treatment
Next we analyzed the capacity of dextran-based CD40 treatment to control tumors 
in a therapeutic setting. Mice were inoculated with tumor cells and treated with 
anti-CD40 when tumors were palpable. In figure 4A and B the outgrowth of the 
tumors and the survival of mice following the different treatments are depicted. 
The majority of mice treated with high dose systemic anti-CD40 antibody and 
low dose Montanide anti-CD40 antibody eradicated their tumor, whereas the 
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majority of non-treated mice and mice treated with low-dose dextran-particle 
anti-CD40 antibody succumb to tumor burden. 
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Figure 4: Tumor eradication by low dose, local anti-CD40 antibody treatments. Survival and tumor growth of 
tumor-bearing mice after treatment with 30 µg of anti-CD40 agonist Ab in Montanide or 30 µg of anti-CD40 agonist 
Ab in dextran-based microparticles , subcutaneously, compared with high dose (3*100 µg) intravenously, 8 days 
after tumor inoculation. Data presented as survival with 8 or 9 mice per group. (A); the Kaplan–Meier test revealed 
a significant difference between local Montanide treatment and no treatment, and between intravenous treatment 
and no treatment (P = 0.04 and P= 0.01, respectively). (B); data presented as tumor growth in each mouse, 8 
or 9 mice per group, number of mice that died of tumor burden indicated in top left-hand corner. (A,B);  data 
representative of 3 independent experiments.
There is a clear delay in tumor outgrowth in most of the mice in the dextran-
particle treated group compared to the non-treated group (Fig 4B), but treatment 
is not effective enough to cure the mice. Most likely due to the slower release 
kinetics of the dextran-particles, and the slower kinetics of the anti-tumor T cell 
response, the treatment was suboptimal for tumor-eradication. To determine if 
the slow kinetics were responsible for the poor tumor eradication we treated 
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mice with a similar dose of anti-CD40 antibody in dextran-particles with faster 
release kinetics, namely the 70% water containing particles. As is shown in 
figure 4C, the faster release particles did not lead to better tumor control. 
Treatment with a higher dose of dextran particles.
Since previous experiments showed that serum levels of antibody and liver 
enzymes were decreased after treatment with 50% water containing dextran-
particles compared to Montanide, we conjectured that there was a window in 
which we could use a higher dose of anti-CD40 antibody encapsulating dextran-
particles in order to achieve improved anti-tumor responses without increasing 
adverse systemic side-effects from the antibody levels in the serum. We analyzed 
the tumor eradication after treatment with a 3 times higher dose of antibody 
in dextran-particles. Since the antibody to dextran-ratio was fixed, we injected 
tumor-bearing mice with 3 times more dextran particles. Unexpectedly, the 
tumor in the mice treated with the higher dose of dextran and antibody grew 
out faster than the untreated group, as is shown in figure 5. Simultaneously, the 
mice in this group developed large ulcerating subcutaneous lumps at the site 
of injection. This phenomenon was also observed in mice treated with control 
dextran-particles, and mice treated with lower doses of dextran particles, but to 
a much lesser extent. The overall outcome of these experiments led us to conclude 
that dextran-based microparticles induce undesirable local side-effects and are 
therefore not recommended as slow-release vehicles for tumor immune therapy. 
Figure 5: High dose of dextran-based microparticles 
enhances tumor-outgrowth.Survival of tumor-bearing 
mice after treatment of 100 µg of anti-CD40 antibody in 
dextran-based microparticles, compared to non-treated 
mice. The Kaplan-Meier test revealed a significant 
difference between microparticles treated mice and non-
treated mice (P=0.01) 9 mice per group. 
Discussion
We here report the comparison of dextran-based microparticles and Montanide 
ISA-51 for delivering immune-modulating antibodies in the tumor-draining 
area in order to activate the anti-tumor T cell response. By comparing dextran-
particles with the previously described slow-release agent Montanide-ISA-51 for 
release kinetics, adverse side-effects, and ability to activate immune cells and 
mediate tumor eradication, we determined whether dextran-particles could be 
a suitable slow-release method for the use in tumor immune therapy. We show 
that dextran-particles are a very effective slow-release agent, with valuable 
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options to tailor release kinetics and thereby decrease the adverse systemic side-
effects of the immune-modulating antibody. However, the dextran-microparticles 
unfortunately cause serious local inflammatory side-effects, associated with 
enhanced tumor outgrowth and ulcerating subcutaneous swellings. 
We contemplated that the enhanced outgrowth of the tumor cells could be caused 
by two possible, not mutually exclusive, processes. The ulcerating lumps formed 
at the injection site can cause attraction of innate immune cells. In a previous 
study by de Groot et al. histological analysis of dextran-associated subcutaneous 
masses determined the infiltrate to be macrophages and neutrophils [22]. 
Innate immune cells, like macrophages and neutrophils have been implicated 
in creating tumor-promoting micro-environments [23, 24]. The second process 
possibly responsible for the enhanced outgrowth of tumors is the presence of 
dextran near the tumor, serving as an additional source of nutrient for the tumor 
cells. Dextran is composed of large sugar molecules that can be broken down to 
glucose. Tumor cells reportedly have an elevated glucose metabolism, growing 
faster in the presence of higher level of glucose [25, 26]. 
The results obtained in this study are contradictory to an earlier study in which 
tumor bearing mice were treated with dextran-based microparticles containing 
the cytokine IL-2 [27]. In this study efficient anti-tumor responses were found, 
and no adverse events of dextran were observed. The model used in this study was 
a lymphosarcoma, which was injected intraperitoneally, like the IL-2 containing 
microparticles. The fact that both tumor and microparticles are in the peritoneal 
cavity in this model, compared to the subcutaneous location in our model, could 
explain the differences found. In the peritoneal cavity, the proximity of the 
microparticles to the tumor was reduced, and the microparticles were dispersed 
through the cavity, and did not form a depot as they did subcutaneously. 
Additionally, the glucose metabolism of the two tumor models could be different. 
Dextran-microparticles could be a potentially attractive formulation for other 
purposes, such as vaccination, considering the efficient activation of CD8+ T 
cells by anti-CD40 antibodies, combined with lower serum levels of antibody, 
and lower systemic toxicity. Since the adverse events were shown to be dextran-
specific and deteriorated with increased amounts of injected dextran, it is 
possible, that by altering the protein to dextran-ratio, dextran-microparticles 
can be prepared with less adverse events as the particles described in this study. 
In the present study, we show that dextran-based microparticles are an effective 
slow-release delivery system for antibodies. The delivery can be tailored, 
and the amount of antibodies in the serum remains low, thereby reducing 
antibody-mediated toxicity. However, adverse events caused by the dextran, 
make this delivery system less suitable for the use in tumor-immunotherapy. 
Since Montanide ISA-51 does not display these disadvantages, we conclude 
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that Montanide is preferred over dextran-based microparticles as slow-release 
delivery system for the use in tumor-treatment. This study shows that local 
CD40 agonistic antibody delivery is a very potent approach for cancer treatment, 
but great care should be taken in selecting a proper slow-release delivery system 
for use in tumor-immunotherapy.
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Abstract
In recent years, it has become apparent that in subjects with growing tumors, 
there is a balance between tumor-eradicating and tumor-promoting immunity. 
The key players in maintaining this balance are mainly present in the tumor 
microenvironment and the tumor-draining lymph node. Interventions aimed at 
shifting the balance towards tumor-eradicating immunity, are therefore most 
efficient when targeted directly to this area as shown in this thesis. As immune-
modulating therapy has been shown to cause many adverse side-effects when 
administered systemically, we strongly advocate the further development of 
local treatment for tumor- immune therapy. 
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Introduction:
 Lymph nodes (LNs) are organs comprised of lymphoid cells that occupy strategic 
positions throughout the body and play a pivotal role in the immune system. 
LNs act as sentinels within the system, filtering the afferent lymph and bringing 
together cells of the innate and adaptive immune system interact, which in case 
of acute infection, leads generally to robust priming of naïve T cells. Tumor-
draining LNs (TDLNs) have a dubious position as they can induce anti-tumor T 
cell responses but are at the same time under the direct influence of the tumor 
microenvironment and can act as route for malignant cells towards distant 
organ metastasis1-3 Because of this, the controversial role of surgical removal of 
sentinel LNs has been a matter of debate for decades4. 
The concept of tumor immune surveillance, the potential of the immune system to 
keep the formation and outgrowth of malignant cells in check, has been described 
as early as 1891, by William Coley, and has waned and recurred in scientific 
publications several times over the last 120 years. The experimental evidence 
supporting the concept of immune surveillance is still growing (see for recent 
reviews Swann and Smyth5 and Vesely MD et al6) and was recently extended 
by Schreiber and colleagues who described the association of tumor cells and 
lymphocytes actively inhibiting the formation and progression of transformed 
cells and ultimately causing selective evolution of tumor cells that can evade 
the immune response, a phenomenon called cancer immunoediting7,8. Based on 
this knowledge many tumor intervention treatments have been designed and 
studied involving immunotherapy in both pre-clinical models and clinical trials 
with varying successes and pitfalls. The potential for targeted immunotherapy 
to the tumor area and more specifically to the TDLN has been brought forward 
in recent years. In this review we would like to discuss the latest insights into 
tumor immune therapy and the strategies and advantages of local targeting. 
Balancing induction and suppression of tumor immunity.
The growth of a tumor often coincides with both the stimulation of anti-tumor 
T cell responses and the parallel (and often unwanted) induction of immune 
suppression. Both processes take place mainly in the tumor area and TDLN. 
This balance between T cell priming and suppression is one of the key aspects in 
disease prognosis9. 
In mice the critical importance of the adaptive immune system, especially of T 
cells, to prevent tumor development was proven by sophisticated experimental 
tumor models involving the ablation of the specific regulators of the adaptive 
immune system10-12. In cancer patients, significant numbers of T cells specific 
to tumor associated antigens have been identified and found to be correlated 
with improved prognosis9,13-17. Tumor antigens are presented by APCs within 
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the tumor or are first carried from the tumor by tumor cells or APCs  traveling 
through lymphatic channels to become cross-presented in LNs to T cells18,19,20. 
The APCs in the tumor mass and TDLN generally display a certain level of 
maturation due to the presence of endogenous danger signals from the growing 
tumor, such as heat shock proteins and uric acid from decaying tumor cells. 
Compared to pathogenic infections however, the APC maturation signals are 
much lower, which can lead to inadequate T cell priming20-23. Especially, the 
lack of costimulatory signals (e.g. CD80/86) has been linked to dysfunctional T 
cells. Likely, also the lower production of the pro-inflammatory cytokines IL-12 
and IFN-gamma20,21,23 contributes to the low state of T cell activation to tumor 
antigens. This phenomenon of inadequate T cell activation has led to different 
nomenclatures for these T cells including anergic T cells, division arrest T cells, 
incomplete differentiated T cells, dysfunctional T cells and tolerised T cells. In 
tumor settings anergic T cells are characterized by inadequate effector function 
such as the lack of cytolytic molecules (e.g. perforin or granzyme B), expression 
of low levels of IFN-γ and a division arrest phenotype, which all contribute to 
reduced capacity to kill tumor cells19,24-28. Besides lower “quality” of T cell priming 
by APCs, both animal models and human studies show that TDLN also harbor 
lower numbers of DC. Nevertheless, tumor specific T cells with full cytotoxic 
capacity have been described with respect to phenotype and function9,25,29, 
suggesting that transformed cells can lead to proper T cell activation providing 
hope for immunotherapeutic strategies. 
Immune suppression within the tumor microenvironment and TDLN is 
characterized by an unfavorable concoction of immunosuppressive cytokines, 
growth factors, and various suppressing cell populations. Well studied 
suppressive cytokines, produced by tumors or tumor associated macrophages, are 
IL-10, TGF-β, VEGF and IL-6. Chemokines, such as CCL2 and CXCL8, secreted 
by monocytes and tumor associated macrophages, cause tumor progression, 
myeloid derived suppressor cell (MDSC) and macrophage infiltration and 
tumor angiogenesis. Effector T cell suppression is mediated by regulatory T 
cells, MDSCs and tolerogenic DC21,22,30. A special type of factor that inhibits 
the induction of pro-inflammatory immune responses is IDO (indoleamine 2,3 
dioxygenase). IDO, expressed on plasmacytoid DC and some types of tumor cells, 
causing inhibition of T cell proliferation by enzymatically degrading tryptophan 
leading to tryptophan starvation. This can also lead to conversion of CD4+ T 
cells to Tregs in TDLN31. 
The increased presence of regulatory T cells (Tregs) in TDLN compared to non-
draining LN has been well established in both animal models and cancer patients, 
in which accumulation of Tregs in DLN of colorectal cancer patients and not 
in tumor or peripheral blood is correlated with disease progression22,30,32,33. Treg 
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accumulation in tumor bearing animals can result from either proliferation of 
natural, thymic differentiated Tregs or conversion of naïve CD4+ T cells into 
Tregs. The mechanisms of Treg suppression are not fully understood yet, but can 
include IL-2 deprivation, expression of CTLA-4, and secretion of IL-10 and/or 
TGF-β. Recent publications showed that Tregs can also limit DC, NK and CD8+ 
T cell numbers by direct granzymeB and perforin dependent killing in TDLN31,34. 
Further limiting the immune response is the fact that in elderly patients 
(the majority of cancer patients), the immune system has undergone aging35. 
This phenomenon, also called immunosenescence, is characterized by loss of 
immunocompetence which limits immune resistance not only to tumors but also 
to pathogens such as influenza virus, respiratory synticium virus, pneumococci 
and tubercle bacilli as well as to, chronic persistent viruses such as CMV. 
Therapies designed in animal models to boost the immune systems against tumors 
may be imperfect in elderly patients, because of this phenomenon, and more 
vigorous therapies or different strategies may be necessary. In this aspect, it is 
interesting to note that Belloni et al recently reported age-dependent differences 
in side-effects to systemic anti-IL10 receptor antibodies. IL-10 inhibition caused 
high mortality in older animals, whereas no mortality was observed in young 
animals. Since cancer patients are often older individuals, these results imply 
that systemically blocking the IL-10 receptor should be evaluated carefully36.
Local Immune therapy: targeting the tumor micro-environment and 
draining lymph nodes.
Decrease of adverse side-effects by local treatment versus systemic treatment.
Recent reports describe the dangers of toxic side-effects of systemic immune 
activating treatments, emphasizing the need for more targeted therapies. 
Together with the growing evidence defining the local suppressive effects of the 
tumor microenvironment and the unique position of the tumor draining lymph 
node, this calls for exploring the potential of immune intervention strategies 
that act mainly locally.
Many different strategies have been proposed to re-activate the TDLN resident 
anergic T cells, and overcome tumor induced immune suppression, some of 
which specifically target the tumor, tumor draining area and/or tumor draining 
LN. Many of these strategies were first described in systemic applications of 
immunostimulatory strategies in experimental models and later in clinical trials. 
Numerous pre-clinical studies have described that such systemic therapies can 
overcome T cell anergy, either by activating DCs (using TLR-ligands or agonistic 
CD40 antibody), blocking inhibitory signals (blockade of CTLA-4, PD-1 or 
TGF-β), or addition of pro-inflammatory cytokines (IL-12, IFN-α or IL-2) 37,38 
resulting in tumor eradication. Clinical trials, however, did not show a similar 
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success rate in clearing tumors as observed in some animal models. Frequently, 
the relative dose of immune stimulating reagents used in rodents is higher 
then the maximum tolerated dose used in humans (correlated for body weight). 
Immunologists using animal models are often less focused on side effects than on 
efficacy. However, more researchers are starting to become aware that in order 
for pre-clinical animal models to be more representative to the human situation, 
lower doses of immune stimulating agents should be used, and toxic side-effects 
in animal models should be meticulously analyzed,36,39,40 as described in chapter 
2. 
Moreover, systemic activation of the immune system can cause serious toxicity 
as shown in a number of clinical trials and animal studies. An example is the 
catastrophic clinical trial with CD28 superagonist TGN1412. Indeed, potent 
systemic activation of the entire immune system is unadvisable, and should be 
applied with utmost caution41. In many other studies, adverse events caused 
by systemic immune activation were dose-limiting and hampered the efficiency. 
Agonistic antibodies against CD40 and cytokines IL-12 and IL-2 have all been 
described to have potent effects in enhancing the anti-tumor T cell response, and 
all have been causing severe toxicity in patients after systemic administration42-44. 
Even GM-CSF administration, which is not directly immune activating and 
therefore contains a lower risk of causing toxicity, has been shown to have 
adverse effects when injected systemically. Serafini et al published a paper in 
which data was presented showing the increase in MDSC in subjects treated 
with high dose systemic GM-CSF, causing an impaired immune response45.
Specific targeting of the tumor microenvironment. 
One way of reducing systemic side effects is to target exclusively the tumor 
lymphoid drainage area. For instance, CpG, a toll-like receptor 9 ligand, 
injected locally enhances DC maturation and migration to TDLN40,46-48. When 
compared to other administration routes, local injection was superior in DC 
maturation, T cell priming and tumor eradication, in a preclinical model48. In 
a clinical trial, CpG was administered intradermally directly adjacent to the 
scar of melanoma resection, before the sentinel lymph node (SLN) resection, and 
the immune response was analyzed in the SLN and PBMC. Patients displayed 
higher numbers of DC in the SNL associated with upregulation of costimulatory 
molecules, increased release of pro-inflammatory cytokines and reduction in 
immunosuppressive Treg frequencies. Fifty percent of these patients had a 
measurable pro-inflammatory T cell response against melanoma specific tumor 
antigens in the SLN and in 40% of the patients, a T cell response was also found 
in blood. This therapy was well tolerated by patients. In another clinical trial, 
intratumoral injection of CpG was combined with low dose, local irradiation. 
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An increase in tumor specific T cells was detected in PBMC of patients, and 
objective responses were found49 50. 
Induction of inflammation in the tumor lymph node draining area leads to 
upregulation of several factors, like CCR7 on DC and CCL21 on lymphatic 
endothelial cells which in turn lead to enhanced migration of DC to the lymph 
node51,52. The influx of mature DC into the LN causes the lymph node to increase 
in size and cellularity, called reactive lymph node. The inflammatory state of the 
reactive lymph node influences the activation of T cells, as described recently. 
Especially important for memory recall responses, T cells that had developed in 
the presence of a reactive lymph node had a significant quantitative advantage 
over T cells in mice without a reactive lymph node53(chapter 4). In animal models 
and clinical trials, genetically engineered tumor cells secreting GM-CSF, CTLA-
4 blocking antibody or CCL20 (a DC attracting chemokine), have been studied 
as local treatment. By injecting the irradiated tumor cells close to the tumor, 
they serve as antigen and antibody secreting depot to the TDLN, and cause 
activation of effective anti-tumor T cell responses and tumor eradication, with 
lower treatment associated toxicity than upon systemic administration54,55. 
Previously we reported that targeting the tumor-draining area with a low dose 
of agonistic CD40 antibody in a slow-release formulation overcomes tumor-
induced immune suppression and induces excellent systemic tumor-specific T 
cell responses capable of killing metastatic cells located elsewhere in the body. 
Local therapy therefore can thus lead to systemic responses, with only a fraction 
of the toxic side-effects56(chapter 2). Local, slow-release administration of CTLA-
4 blocking antibody is also capable of activating tumor-eradicating CD8+ T cells 
as a monotherapy, as described in chapter 3. This treatment severely reduced the 
serum-levels of CTLA-4 blocking antibody compared to systemic administration, 
reducing the risk of auto-immune related side-effects. 
It is likely to assume that slow-release formulations are functional in targeting 
immune stimulating agents to the TDLN, because they keep the tumor-draining 
area, or regional basin, in a pro-inflammatory status for a prolonged period of 
time, allowing the T-cell response to fully develop and the immune suppression 
to remain blocked. In addition, the concentration of immune stimulatory agent 
remains high only locally and not systemically, thereby preventing undesirable 
side-effects and unspecific overstimulation. Slow-release formulations such as 
montanide ISA 51, have been studied for their efficiency in delivering immune 
modulating antibodies (such as anti-CD40) to the TDLN with strong systemic 
anti-tumor responses as a result, but no systemic toxicity56(chapter 2 and 
3).  The discovery of several new sustained release systems, such as PLGA-
based microparticles, opens up possibilities for targeted treatments which can 
be explored for tumor immunotherapy. 57,58 However, as described in chapter 
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5, dextran-based microparticles have unexpected local side-effects, causing 
enhanced tumor-outgrowth, making them inferior as slow-release delivery 
system to Montanide. Slow-release formulations should therefore be carefully 
analyzed for their suitability in tumor-area targeted therapy. 
Another aspect that strengthens the use of local immunotherapy lies in the 
fact that many immunosuppressive mechanisms that inhibit tumor-specific 
effector T cell responses, as described before, are not uniquely operable in the 
tumor microenvironment, but are mechanisms that have evolved to keep the 
immune system from attacking self tissue. Interfering with these interactions 
on a systemic scale, therefore, is risky. Not surprisingly, examples of systemic 
immunostimulatory tumor immunotherapy causing severe autoimmunity are 
abundant 38,59,60.
Potential hurdles for local immunotherapy. 
Recent studies have shown that elevated levels of MDSCs are present in cancer 
patients and tumor bearing mice. Since these cells are described to incite 
systemic suppression, rather then local suppression, targeting of the TDLN is 
not likely to overcome suppression by these cells61,62. Several studies mentioned 
in this review describing local targeting of the TDLN have been able to overcome 
local suppression by activating robust anti-tumor T cell responses, which are 
able to withstand systemic suppression and eradicate distant tumors. However, 
systemic suppression by MDSC was not analyzed in these studies, and might 
have been weak, where in other models, it could be stronger, and therefore 
harder to overcome. 
Targeting TDLN might cause the practical problem of inaccessibility of a draining 
node, since in several types of cancer  TDLN’s are not within easy reach. In 
order to solve this problem, new approaches are being studied such as delivery of 
nanoparticles coupled to tumor-antigen-specific antibodies, which can be injected 
systemically but, deliver their immuno-modulating content selectively into the 
tumor from where it will eventually drain to the TDLN40,46.  
Concluding remarks.
The tumor microenvironment and especially the TDLN are the key locations for 
important anti-tumor immunological processes, and therefore the quintessential 
targets for immune-modulating therapies in tumor bearing subjects. Since both 
priming of tumor-specific T cell responses and immune suppression occur in this 
area, local therapies designed to balance this equilibrium toward more effective 
anti-tumor T cell response will be most efficient. Whether tumor eradication is 
most efficiently achieved by promoting the stimulation of DCs presenting tumor 
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antigens, enhancing tumor antigen presentation, abolishing immune suppressive 
pathways, or a combination of these, remains to be defined experimentally and 
clinically. Notably, since most of the tumor-immunotherapy strategies harbor 
the risk of causing serious toxicity and/or auto-immunity, targeting the TDLN 
and/or the tumor microenvironment instead of systemic administration should 
be a focus of future immuno-therapeutic strategies. 
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Nederlandse samenvatting voor niet-ingewijden
Ons afweersysteem is ontstaan om ons te beschermen tegen ziekteverwekkers 
zoals virussen en bacteriën. Het bestaat uit een groot aantal verschillende 
soorten cellen met elk een specifieke functie, die moeten samenwerken om 
ziekteverwekkers te kunnen herkennen en opruimen. Het moeilijkste van dit 
proces voor de afweercellen is onderscheid te maken tussen gezond weefsel en 
onschuldige indringers (zoals bacteriën in je darmen of deeltjes uit je voeding) 
en ziekteverwekkers. Als het afweersysteem gaat reageren tegen gezond 
weefsel kan auto-immuniteit ontstaan, en als het afweersysteem reageert tegen 
onschuldige indringers, dan kunnen allergieën ontstaan. Om het onderscheid 
te kunnen maken tussen gezond/onschuldig en ziek moeten afweercellen goed 
communiceren. Met een strak gereguleerde balans tussen activeren en afremmen 
moeten ze tot de juiste actie overgaan.
Sinds een tijd weten we dat het afweersysteem ook belangrijk is bij kanker. Bij 
patiënten die een verminderde weerstand hebben door medicatie (bijvoorbeeld 
na transplantatie) of ziekte (bijvoorbeeld bij AIDS patiënten) ontstaan sneller 
tumoren. In veel kankerpatiënten en proefdiermodellen van kanker zijn bewijzen 
gevonden van een afweerrespons tegen de kankercellen. De afweerrespons is niet 
sterk genoeg om tumoren volledig op te kunnen ruimen. Dit komt voor een groot 
deel door de strakke regulering van de balans van het afweersysteem. Doordat 
kankercellen lichaamseigen cellen zijn en er geen sprake is van duidelijke schade 
zoals dat bij virale of bacteriële infectie wel het geval is, blijft de balans van het 
afweersysteem op afremmen in plaats van activeren. In dit proefschrift wordt 
onderzoek beschreven naar therapieën om de afweerrespons tegen tumoren te 
activeren, zonder daarbij een te groot risico te lopen op het opwekken van auto-
immuniteit. 
Een bepaald soort cel van het afweersysteem, de dendritische cel (DC), fungeert 
als verkenner in het lichaam. Deze cellen bevinden zich op alle plaatsen waar 
indringers het lichaam zouden kunnen binnendringen. Een DC speurt continue 
de omgeving af en verzamelt materiaal door bijvoorbeeld dode cellen op te 
nemen. Als er veel dode cellen en schade zijn, bijvoorbeeld bij een infectie, dan 
worden DCs geactiveerd waarna ze migreren naar de dichtstbijzijnde lymfeklier. 
Daar bevinden zich vele andere soorten afweercellen die met de DC kunnen 
communiceren. De DC laat kleine stukjes van het materiaal dat hij heeft 
opgenomen aan zijn celoppervlakte zien. Daarmee laat de DC aan de afweercellen 
in de lymfeklier zien wat er in het lichaam aan de hand is. Meerdere cellen 
scannen de DCs; wanneer ze iets herkennen, gaan ze tot actie over. Een bepaald 
soort cel van het afweersysteem, de CD8 T cel, kan, als hij het juiste signaal van 
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de DC heeft gekregen, overgaan tot het doden van geïnfecteerde cellen. Elke 
CD8 T cel herkent iets anders; pas als de CD8 T cel in contact is gekomen met 
een geactiveerde DC die dat specifieke stukje (antigeen) heeft gepresenteerd, en 
daarbij nog enkele activerende signalen heeft gegeven, gaat deze cel heel hard 
delen. Als er voldoende cellen zijn die allemaal dat specifieke stukje antigeen 
herkennen, gaan de CD8 T cellen door het lichaam op zoek naar cellen die ook 
dat antigeen hebben en maken deze cellen dood. Die stukjes antigeen kunnen 
afkomstig zijn van virussen of bacteriën, maar dat kunnen ook stukjes materiaal 
van kankercellen zijn. 
Als alle cellen die de stukjes antigeen hebben zijn opgeruimd, gaat het grootste 
deel van de CD8 T cellen dood. Een klein deel blijft leven en wordt geheugencellen. 
Deze geheugencellen reageren veel sneller wanneer eenzelfde virus/bacterie 
nogmaals het lichaam binnendringt. Dit is het principe van immuniteit tegen 
bepaalde ziekte en ook het principe van vaccinatie. Door bewust afweercellen te 
activeren tegen stukjes van bepaalde virussen of bacteriën kunnen we zorgen 
dat er geheugencellen ontstaan, zodat ons afweersysteem adequaat en snel kan 
reageren als we later met dezelfde virussen of bacteriën in aanraking komen. 
Hoofdstuk 2: Lokale toediening van anti-CD40 activerend antilichaam 
in een langzame afgifte depot geeft goede tumor opruiming en sterk 
verlaagde toxiciteit
In hoofdstuk 2 wordt een manier beschreven om de CD8 T cellen die kankercellen 
kunnen herkennen te activeren, zonder daarbij het hele afweersysteem te 
activeren. In een proefdiermodel laten wij zien dat er in de poortwachter 
lymfeklier, de lymfeklier die het dichtst bij de tumor ligt, tumor-specifieke CD8 
T cellen zijn. Deze tumor-specifieke CD8 T cellen zijn niet voldoende geactiveerd 
en hebben niet genoeg gedeeld om de tumor op te kunnen ruimen. In eerdere 
onderzoeken is al aangetoond dat als je deze muizen injecteert met anti-CD40 
activerend antilichaam, de CD8 T cellen wel voldoende worden geactiveerd 
en de tumor gaan opruimen. Dit werkt als volgt; de anti-CD40 activerende 
antilichamen binden aan het molecuul CD40 op de DCs, en geven een activerend 
signaal. In de poortwachter lymfeklier zitten DCs die stukjes van de tumorcellen 
presenteren, en als deze door de anti-CD40 activerende antilichaam worden 
geactiveerd, kunnen ze op hun beurt de tumorspecifieke CD8 T cellen activeren. 
Het probleem met deze therapie is dat het anti-CD40 activerende antilichaam 
in het hele lichaam alle DCs activeert, en nog een heleboel andere afweer cellen, 
die ook het molecuul CD40 hebben. Dit geeft onnodige schade en een verhoogd 
risico op auto-immuun ziektes. Ons onderzoek toont aan dat als je het anti-CD40 
antilichaam inspuit dicht bij de tumor en de poortwachter lymfeklier, in een 
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emulsie waaruit het antilichaam langzaam vrijkomt, de tumorspecifieke CD8 
T cellen door de DCs in de poortwachter lymfeklier worden geactiveerd, maar 
dat er niet zoveel van het antilichaam in de rest van het lichaam terecht komt 
dat alle immuuncellen geactiveerd raken. De bijwerkingen van deze manier van 
toediening zijn veel lager dan wanneer het anti-CD40 antilichaam in het bloed 
wordt ingespoten. Daarnaast is veel minder van het antilichaam nodig bij lokale 
toediening voor een goed effect. Bovendien, doordat de tumor-specifieke CD8 T 
cellen in de lymfeklier goed worden geactiveerd en gaan delen, kunnen ze daarna 
in het hele lichaam op zoek gaan naar tumorcellen. Eventuele uitzaaiingen 
kunnen dan wel worden opgeruimd door de CD8 T cellen, ook als het anti-CD40 
antilichaam er niet bij in de buurt komt. 
Hoofdstuk 3: Lokale toediening van CTLA-4 blokkerend antilichaam in 
een langzame afgifte depot geeft goede tumor opruiming via activering 
van CD8 T cellen
In hoofdstuk 3 wordt dezelfde lokale toediening in een emulsie toegepast met 
CTLA-4 blokkerend antilichaam. CTLA-4 is een molecuul op de oppervlakte van 
T cellen dat betrokken is bij de regulering van activatie van T  cellen. CTLA-
4 geeft een remmend signaal aan T cellen om responsen tegen lichaamseigen 
cellen te voorkomen. Het blokkeren van CTLA-4 wordt gebruikt om bij tumor-
specifieke T cellen die remmende werking op te heffen. Dit antilichaam is onlangs 
goedgekeurd in de Verenigde Staten voor gebruik in patiënten met vergevorderde 
huidkanker. Bij deze patiënten wordt het blokkerende antilichaam toegediend 
in het bloed. Er zijn goede resultaten geboekt met remming van de groei van 
tumoren en activering van de T cellen tegen tumoren. Een groot deel van de 
patiënten die wordt behandeld met dit antilichaam krijgt ook last van auto-
immuun gerelateerde bijwerkingen, zoals ernstige diarree en huidontstekingen. 
Dit is logisch omdat het blokkeren van CTLA-4 niet alleen bij tumor-specifieke 
T cellen gebeurt, maar bij alle T cellen. Wij laten zien dat voor het CTLA-4 
blokkerende antilichaam hetzelfde geldt als voor het anti-CD40 activerende 
antilichaam. Als je het dicht bij de tumor en de poortwachter lymfeklier spuit 
in een emulsie die voor langzame afgifte zorgt, krijg je met een veel lagere dosis 
van het antilichaam een even goed effect op tumoren als bij een toediening van 
een hoge dosis in het bloed. Dit geeft minder bijwerkingen en verlaagt het risico 
op auto-immuniteit. 
Hoofstuk 4: De invloed van een lokaale geactiveerde lymfeklier op de 
ontwikkeling van de CD8 T cellen
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In hoofdstuk 4 wordt beschreven wat de bijdrage is van het geactiveerde milieu 
van een lymfeklier in een afweerrespons. Tijdens een infectie wordt de lokale 
lymfeklier geactiveerd. Door een sterke influx van cellen zwelt de lymfeklier op 
en worden allerlei activerende stoffen uitgescheiden. In ons onderzoek hebben 
wij een methode opgezet waarmee we precies de invloed van deze geactiveerde 
omgeving kunnen bepalen. CD8 T cellen worden kort in kweekschalen geactiveerd 
onder precies dezelfde omstandigheden, waarna ze in muizen met of muizen 
zonder een geactiveerde lymfeklier worden gespoten. De cellen worden daarna 
op verschillende momenten geanalyseerd op aantallen, capaciteit tot het doden 
van hun doelwit cellen en ontwikkeling tot geheugencellen. De resultaten laten 
zien dat de CD8 T cellen in muizen met een geactiveerde lymfeklier voordeel 
hebben ten opzichte van de T cellen in muizen zonder geactiveerde lymfeklier. 
Dit uit zich vooral in een grotere hoeveelheid geheugencellen en een snellere en 
sterkere reactie van deze geheugencellen op een tweede infectie. 
Hoofdstuk 5: Een emulsie van olie in water is geschikter om antilichamen 
voor tumor therapie langzaam af te geven dan microscopisch kleine 
bolletjes opgebouwd uit dextran-suikers 
In hoofdstuk 5 wordt onderzoek beschreven waarin twee manieren om 
antilichamen langzaam af te geven in het lichaam met elkaar worden vergeleken. 
In hoofdstuk 2 en 3 wordt beschreven dat lokale toediening van anti-CD40 
activerend antilichaam en CTLA-4 blokkerend antilichaam in een langzame 
afgifte formulering een goede tumor-specifieke T cel activatie geeft met veel 
minder bijwerkingen. De langzame afgifte formulering die wij in de studies 
beschreven in hoofdstuk 2 en 3 gebruikten is Montanide, een olie in water emulsie. 
Hier vergeleken wij Montanide met een nieuwe methode, namelijk microscopisch 
kleine bolletjes gemaakt van dextran-suikers (dextranbolletjes), waarin het 
antilichaam is verpakt. Deze bolletjes vallen in het lichaam vanzelf langzaam 
uit elkaar waardoor het antilichaam vrij komt. De snelheid van uit elkaar vallen 
kan worden bepaald door de manier waarop de bolletjes worden gemaakt, met 
meer of minder water in het mengsel. Wij beschrijven dat de langzame afgifte van 
anti-CD40 antilichaam uit de dextran-bolletjes goed werkt; zelfs bij lage snelheid 
van uit elkaar vallen worden nog steeds tumor-specifieke T cellen geactiveerd. 
De bijwerkingen van de therapie met deze dextranbolletjes zijn zelfs nog minder 
dan bij de montanide-emulsie. Helaas blijken de dextranbolletjes toch minder 
geschikt voor gebruik als tumor-therapie aangezien de tumoren sneller gingen 
groeien van de dextran-bolletjes die er dichtbij werden gespoten. Het feit dat 
de langzame afgifte efficiënt is, is dus nog geen maat voor de goede werking bij 
tumor-therapie. Dit onderzoek geeft aan dat Montanide emulsie meer geschikt 
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is voor tumor-therapie dan dextran-bolletjes.
 
Hoofstuk 6: Discussie
In het laatste hoofdstuk worden alle onderdelen van het proefschrift samengevat 
en bediscussieerd aan de hand van vergelijkbare studies uit de literatuur. In een 
opinie artikel bespreek ik onderzoek waarover de afgelopen jaren is gepubliceerd. 
Ik gebruik die publicaties, samen met onze eigen bevindingen, om de stelling te 
onderbouwen dat immuun-activerende therapie van tumoren het beste gericht 
kan worden op de poortwachter lymfeklier in plaats van in het bloed gespoten 
te worden. 
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De auteur van dit proefschrift werd geboren op 13 juni 1975 in Grave. In 1993 
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Ossendorp, binnen de groep Tumorimmunologie in het LUMC. 
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Nawoord:
Wie had gedacht, toen ik 12.5 jaar geleden bij de tumorimmunologie-groep als 
analist kwam werken, dat ik nu een proefschrift uit zou delen? Ikzelf in ieder 
geval niet. Maar na al die jaren ben ik nog steeds heel blij en dankbaar voor de 
keuzes die ik heb gemaakt, de mensen waarmee ik heb samengewerkt, en de 
kansen die ik heb gekregen.
Professor Melief, beste Kees, bedankt voor het in mij gestelde vertrouwen, de 
inspirerende werkbesprekingen en je aanstekelijke enthousiasme.
Dr. Arens, beste Ramon, bedankt voor je hulp en steun bij de moeilijke laatste 
loodjes, je bent op het goede moment bij ons komen werken!
Mijn paranimfen; Marjolein en Geertje, bedankt dat jullie op zo’n belangrijke 
dag naast me willen staan. Marjolein, we hebben erg fijn samengewerkt, bedankt 
voor al je hulp, ik ken niemand die zo efficiënt werkt als jij! Maar bovenal was het 
heel gezellig samen al die uren in het PDC. Geertje, bijna ons 12.5 jarig jubileum, 
ik ben erg blij dat we nog steeds goede vriendinnen zijn, en het betekent veel 
voor me dat je nu mijn paranimf bent!
Alle collega’s van de tumorimmunologie van de laatste jaren; één van de redenen 
dat ik na al die jaren nog steeds hier werk is de goede sfeer onder de collega’s. Hoe 
groot het verloop ook is, er blijven altijd genoeg prettige, grappige, enthousiaste, 
behulpzame en geïnteresseerde collega’s over binnen de TI. Een speciale vermel-
ding aan de sauna-dames, samen zweten schept een band voor het leven!  
Allemaal heel erg bedankt!
Ook de collega’s van het IHB en van de Klinische Oncologie, erg bedankt voor de 
goede samenwerking, de gezamenlijke werkbesprekingen, de gezellige borrels 
en labuitjes.
Zoals aan de kaft van mijn proefschrift (mijn kleurencode van het PDC) al 
te zien is, heeft het PDC een belangrijke rol gespeeld in mijn promotie. Alle 
medewerkers van het PDC ontzettend bedankt voor de goede samenwerking en 
verzorging van de muizen. De mensen achter de schermen worden nog wel eens 
vergeten, maar ik wil jullie bij dezen in het zonnetje zetten; zonder jullie wordt 
er geen experiment gedaan!
Alle mensen waar ik in de loop der jaren mee heb samengewerkt wil ik graag 
bedanken. Marianne van Stipdonk, Rienk Offringa, Steve Schoenberger, Hans 
Morreau, Wim Hennink, Mies van Steenbergen, Jan-Wouter Drijfhout, Robert 
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Cordfunke, Henny Vermeij en Jolanda Verhagen, allemaal erg bedankt voor 
de goede samenwerking, en jullie bijdrage aan de publicaties die we samen tot 
stand hebben gebracht!
Familie en vrienden, ook jullie hebben bijgedragen; door interesse te tonen in 
wat ik deed, steun als het even tegenzat, en de broodnodige ontspanning.  
Papa en Mama, bedankt voor alles, beter kan ik het niet zeggen. 
And last but not least; John, it’s you and me, together we can do anything.
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